id	sid	tid	token	lemma	pos
ecj-10032	1	1	hrev_master	hrev_master	NOUN
ecj-10032	2	1	[	[	X
ecj-10032	2	2	page	page	NOUN
ecj-10032	2	3	16	16	NUM
ecj-10032	2	4	]	]	PUNCT
ecj-10032	3	1	[	[	X
ecj-10032	3	2	emergency	emergency	NOUN
ecj-10032	3	3	care	care	NOUN
ecj-10032	3	4	journal	journal	PROPN
ecj-10032	3	5	2021	2021	NUM
ecj-10032	3	6	;	;	PUNCT
ecj-10032	3	7	17:10032	17:10032	NUM
ecj-10032	3	8	]	]	X
ecj-10032	3	9	emergency	emergency	NOUN
ecj-10032	3	10	care	care	NOUN
ecj-10032	3	11	journal	journal	PROPN
ecj-10032	3	12	2021	2021	NUM
ecj-10032	3	13	;	;	PUNCT
ecj-10032	3	14	volume	volume	NOUN
ecj-10032	3	15	17:10032	17:10032	NUM
ecj-10032	4	1	abstract	abstract	ADV
ecj-10032	4	2	we	we	PRON
ecj-10032	4	3	describe	describe	VERB
ecj-10032	4	4	the	the	DET
ecj-10032	4	5	case	case	NOUN
ecj-10032	4	6	of	of	ADP
ecj-10032	4	7	a	a	DET
ecj-10032	4	8	64	64	NUM
ecj-10032	4	9	years	year	NOUN
ecj-10032	4	10	-	-	PUNCT
ecj-10032	4	11	old	old	ADJ
ecj-10032	4	12	woman	woman	NOUN
ecj-10032	4	13	admitted	admit	VERB
ecj-10032	4	14	to	to	ADP
ecj-10032	4	15	the	the	DET
ecj-10032	4	16	emergency	emergency	NOUN
ecj-10032	4	17	department	department	NOUN
ecj-10032	4	18	of	of	ADP
ecj-10032	4	19	the	the	DET
ecj-10032	4	20	asst	asst	NOUN
ecj-10032	4	21	-	-	PUNCT
ecj-10032	4	22	spedali	spedali	PROPN
ecj-10032	4	23	civili	civili	NOUN
ecj-10032	4	24	of	of	ADP
ecj-10032	4	25	brescia	brescia	PROPN
ecj-10032	4	26	with	with	ADP
ecj-10032	4	27	fever	fever	NOUN
ecj-10032	4	28	and	and	CCONJ
ecj-10032	4	29	gastrointestinal	gastrointestinal	ADJ
ecj-10032	4	30	symptoms	symptom	NOUN
ecj-10032	4	31	10	10	NUM
ecj-10032	4	32	days	day	NOUN
ecj-10032	4	33	after	after	ADP
ecj-10032	4	34	the	the	DET
ecj-10032	4	35	first	first	ADJ
ecj-10032	4	36	dose	dose	NOUN
ecj-10032	4	37	of	of	ADP
ecj-10032	4	38	chadox1	chadox1	ADJ
ecj-10032	4	39	ncov-19	ncov-19	PROPN
ecj-10032	4	40	vaccine	vaccine	NOUN
ecj-10032	4	41	.	.	PUNCT
ecj-10032	5	1	laboratory	laboratory	NOUN
ecj-10032	5	2	investigations	investigation	NOUN
ecj-10032	5	3	showed	show	VERB
ecj-10032	5	4	severe	severe	ADJ
ecj-10032	5	5	thrombocytopenia	thrombocytopenia	NOUN
ecj-10032	5	6	and	and	CCONJ
ecj-10032	5	7	high	high	ADJ
ecj-10032	5	8	d	d	NOUN
ecj-10032	5	9	-	-	PUNCT
ecj-10032	5	10	dimer	dimer	ADJ
ecj-10032	5	11	,	,	PUNCT
ecj-10032	5	12	while	while	SCONJ
ecj-10032	5	13	an	an	DET
ecj-10032	5	14	abdominal	abdominal	ADJ
ecj-10032	5	15	ct	ct	NOUN
ecj-10032	5	16	scan	scan	NOUN
ecj-10032	5	17	reported	report	VERB
ecj-10032	5	18	a	a	DET
ecj-10032	5	19	partially	partially	ADV
ecj-10032	5	20	occluding	occlude	VERB
ecj-10032	5	21	thrombosis	thrombosis	NOUN
ecj-10032	5	22	of	of	ADP
ecj-10032	5	23	the	the	DET
ecj-10032	5	24	superior	superior	ADJ
ecj-10032	5	25	mesenteric	mesenteric	ADJ
ecj-10032	5	26	artery	artery	NOUN
ecj-10032	5	27	.	.	PUNCT
ecj-10032	6	1	following	follow	VERB
ecj-10032	6	2	treatment	treatment	NOUN
ecj-10032	6	3	with	with	ADP
ecj-10032	6	4	fondaparinux	fondaparinux	NOUN
ecj-10032	6	5	,	,	PUNCT
ecj-10032	6	6	immunoglobulins	immunoglobulin	NOUN
ecj-10032	6	7	and	and	CCONJ
ecj-10032	6	8	high	high	ADJ
ecj-10032	6	9	dosage	dosage	NOUN
ecj-10032	6	10	steroid	steroid	NOUN
ecj-10032	6	11	therapy	therapy	NOUN
ecj-10032	6	12	,	,	PUNCT
ecj-10032	6	13	we	we	PRON
ecj-10032	6	14	observed	observe	VERB
ecj-10032	6	15	a	a	DET
ecj-10032	6	16	rapid	rapid	ADJ
ecj-10032	6	17	improvement	improvement	NOUN
ecj-10032	6	18	of	of	ADP
ecj-10032	6	19	patient	patient	NOUN
ecj-10032	6	20	’s	’s	PART
ecj-10032	6	21	conditions	condition	NOUN
ecj-10032	6	22	.	.	PUNCT
ecj-10032	7	1	an	an	DET
ecj-10032	7	2	elisa	elisa	NOUN
ecj-10032	7	3	assay	assay	PROPN
ecj-10032	7	4	showed	show	VERB
ecj-10032	7	5	the	the	DET
ecj-10032	7	6	presence	presence	NOUN
ecj-10032	7	7	of	of	ADP
ecj-10032	7	8	antibodies	antibody	NOUN
ecj-10032	7	9	against	against	ADP
ecj-10032	7	10	heparin	heparin	ADJ
ecj-10032	7	11	pf4	pf4	NOUN
ecj-10032	7	12	-	-	PUNCT
ecj-10032	7	13	complex	complex	NOUN
ecj-10032	7	14	.	.	PUNCT
ecj-10032	8	1	subsequent	subsequent	ADJ
ecj-10032	8	2	abdominal	abdominal	ADJ
ecj-10032	8	3	ct	ct	PROPN
ecj-10032	8	4	-	-	PUNCT
ecj-10032	8	5	scan	scan	PROPN
ecj-10032	8	6	showed	show	VERB
ecj-10032	8	7	the	the	DET
ecj-10032	8	8	superior	superior	ADJ
ecj-10032	8	9	mesenteric	mesenteric	ADJ
ecj-10032	8	10	artery	artery	NOUN
ecj-10032	8	11	thrombosis	thrombosis	NOUN
ecj-10032	8	12	resolution	resolution	NOUN
ecj-10032	8	13	,	,	PUNCT
ecj-10032	8	14	and	and	CCONJ
ecj-10032	8	15	the	the	DET
ecj-10032	8	16	patient	patient	NOUN
ecj-10032	8	17	was	be	AUX
ecj-10032	8	18	finally	finally	ADV
ecj-10032	8	19	discharged	discharge	VERB
ecj-10032	8	20	after	after	ADP
ecj-10032	8	21	12	12	NUM
ecj-10032	8	22	days	day	NOUN
ecj-10032	8	23	of	of	ADP
ecj-10032	8	24	hospitalization	hospitalization	NOUN
ecj-10032	8	25	.	.	PUNCT
ecj-10032	9	1	several	several	ADJ
ecj-10032	9	2	reports	report	NOUN
ecj-10032	9	3	pointed	point	VERB
ecj-10032	9	4	to	to	ADP
ecj-10032	9	5	the	the	DET
ecj-10032	9	6	venous	venous	ADJ
ecj-10032	9	7	system	system	NOUN
ecj-10032	9	8	as	as	ADP
ecj-10032	9	9	the	the	DET
ecj-10032	9	10	main	main	ADJ
ecj-10032	9	11	district	district	NOUN
ecj-10032	9	12	affected	affect	VERB
ecj-10032	9	13	by	by	ADP
ecj-10032	9	14	vaccine	vaccine	NOUN
ecj-10032	9	15	-	-	PUNCT
ecj-10032	9	16	induced	induce	VERB
ecj-10032	9	17	thrombotic	thrombotic	ADJ
ecj-10032	9	18	thrombocytopenia	thrombocytopenia	NOUN
ecj-10032	9	19	(	(	PUNCT
ecj-10032	9	20	vitt	vitt	PROPN
ecj-10032	9	21	)	)	PUNCT
ecj-10032	9	22	,	,	PUNCT
ecj-10032	9	23	while	while	SCONJ
ecj-10032	9	24	a	a	DET
ecj-10032	9	25	peculiar	peculiar	ADJ
ecj-10032	9	26	feature	feature	NOUN
ecj-10032	9	27	of	of	ADP
ecj-10032	9	28	this	this	DET
ecj-10032	9	29	report	report	NOUN
ecj-10032	9	30	is	be	AUX
ecj-10032	9	31	the	the	DET
ecj-10032	9	32	involvement	involvement	NOUN
ecj-10032	9	33	of	of	ADP
ecj-10032	9	34	the	the	DET
ecj-10032	9	35	mesenteric	mesenteric	ADJ
ecj-10032	9	36	arterial	arterial	ADJ
ecj-10032	9	37	system	system	NOUN
ecj-10032	9	38	.	.	PUNCT
ecj-10032	10	1	further	further	ADJ
ecj-10032	10	2	investigation	investigation	NOUN
ecj-10032	10	3	of	of	ADP
ecj-10032	10	4	vitt	vitt	PROPN
ecj-10032	10	5	’s	’s	PART
ecj-10032	10	6	pathophysiological	pathophysiological	ADJ
ecj-10032	10	7	mechanisms	mechanism	NOUN
ecj-10032	10	8	is	be	AUX
ecj-10032	10	9	mandatory	mandatory	ADJ
ecj-10032	10	10	to	to	PART
ecj-10032	10	11	develop	develop	VERB
ecj-10032	10	12	preventive	preventive	ADJ
ecj-10032	10	13	strategies	strategy	NOUN
ecj-10032	10	14	and	and	CCONJ
ecj-10032	10	15	effective	effective	ADJ
ecj-10032	10	16	treatments	treatment	NOUN
ecj-10032	10	17	.	.	PUNCT
ecj-10032	11	1	introduction	introduction	NOUN
ecj-10032	11	2	to	to	PART
ecj-10032	11	3	counteract	counteract	VERB
ecj-10032	11	4	the	the	DET
ecj-10032	11	5	devastating	devastating	ADJ
ecj-10032	11	6	consequences	consequence	NOUN
ecj-10032	11	7	of	of	ADP
ecj-10032	11	8	the	the	DET
ecj-10032	11	9	sars	sar	NOUN
ecj-10032	11	10	-	-	PUNCT
ecj-10032	11	11	cov2	cov2	PROPN
ecj-10032	11	12	pandemic	pandemic	ADJ
ecj-10032	11	13	,	,	PUNCT
ecj-10032	11	14	major	major	ADJ
ecj-10032	11	15	efforts	effort	NOUN
ecj-10032	11	16	and	and	CCONJ
ecj-10032	11	17	resources	resource	NOUN
ecj-10032	11	18	have	have	AUX
ecj-10032	11	19	been	be	AUX
ecj-10032	11	20	employed	employ	VERB
ecj-10032	11	21	worldwide	worldwide	ADV
ecj-10032	11	22	to	to	ADP
ecj-10032	11	23	research	research	VERB
ecj-10032	11	24	and	and	CCONJ
ecj-10032	11	25	develop	develop	VERB
ecj-10032	11	26	therapies	therapy	NOUN
ecj-10032	11	27	to	to	PART
ecj-10032	11	28	address	address	VERB
ecj-10032	11	29	the	the	DET
ecj-10032	11	30	acute	acute	ADJ
ecj-10032	11	31	and	and	CCONJ
ecj-10032	11	32	sub	sub	ADJ
ecj-10032	11	33	-	-	ADJ
ecj-10032	11	34	acute	acute	ADJ
ecj-10032	11	35	phases	phase	NOUN
ecj-10032	11	36	of	of	ADP
ecj-10032	11	37	the	the	DET
ecj-10032	11	38	disease	disease	NOUN
ecj-10032	11	39	and	and	CCONJ
ecj-10032	11	40	prevent	prevent	VERB
ecj-10032	11	41	further	further	ADJ
ecj-10032	11	42	infection	infection	NOUN
ecj-10032	11	43	spreads	spread	NOUN
ecj-10032	11	44	.	.	PUNCT
ecj-10032	12	1	different	different	ADJ
ecj-10032	12	2	therapeutical	therapeutical	ADJ
ecj-10032	12	3	protocols	protocol	NOUN
ecj-10032	12	4	and	and	CCONJ
ecj-10032	12	5	treatment	treatment	NOUN
ecj-10032	12	6	strategies	strategy	NOUN
ecj-10032	12	7	are	be	AUX
ecj-10032	12	8	available	available	ADJ
ecj-10032	12	9	to	to	PART
ecj-10032	12	10	limit	limit	VERB
ecj-10032	12	11	the	the	DET
ecj-10032	12	12	broad	broad	ADJ
ecj-10032	12	13	spectrum	spectrum	NOUN
ecj-10032	12	14	of	of	ADP
ecj-10032	12	15	clinical	clinical	ADJ
ecj-10032	12	16	consequences	consequence	NOUN
ecj-10032	12	17	of	of	ADP
ecj-10032	12	18	the	the	DET
ecj-10032	12	19	infection	infection	NOUN
ecj-10032	12	20	,	,	PUNCT
ecj-10032	12	21	ranging	range	VERB
ecj-10032	12	22	from	from	ADP
ecj-10032	12	23	interstitial	interstitial	ADJ
ecj-10032	12	24	pneumonia	pneumonia	NOUN
ecj-10032	12	25	to	to	PART
ecj-10032	12	26	thromboembolic	thromboembolic	VERB
ecj-10032	12	27	events.1	events.1	PROPN
ecj-10032	12	28	-	-	PUNCT
ecj-10032	12	29	4	4	NUM
ecj-10032	12	30	preventive	preventive	ADJ
ecj-10032	12	31	measures	measure	NOUN
ecj-10032	12	32	represent	represent	VERB
ecj-10032	12	33	another	another	DET
ecj-10032	12	34	trivial	trivial	ADJ
ecj-10032	12	35	point	point	NOUN
ecj-10032	12	36	in	in	ADP
ecj-10032	12	37	the	the	DET
ecj-10032	12	38	containment	containment	NOUN
ecj-10032	12	39	of	of	ADP
ecj-10032	12	40	sars	sars	PROPN
ecj-10032	12	41	-	-	PUNCT
ecj-10032	12	42	cov2	cov2	PROPN
ecj-10032	12	43	spreading	spread	VERB
ecj-10032	12	44	.	.	PUNCT
ecj-10032	13	1	it	it	PRON
ecj-10032	13	2	is	be	AUX
ecj-10032	13	3	undeniable	undeniable	ADJ
ecj-10032	13	4	that	that	SCONJ
ecj-10032	13	5	the	the	DET
ecj-10032	13	6	development	development	NOUN
ecj-10032	13	7	of	of	ADP
ecj-10032	13	8	effective	effective	ADJ
ecj-10032	13	9	vaccines	vaccine	NOUN
ecj-10032	13	10	within	within	ADP
ecj-10032	13	11	a	a	DET
ecj-10032	13	12	very	very	ADV
ecj-10032	13	13	short	short	ADJ
ecj-10032	13	14	timeframe	timeframe	NOUN
ecj-10032	13	15	represented	represent	VERB
ecj-10032	13	16	a	a	DET
ecj-10032	13	17	landmark	landmark	NOUN
ecj-10032	13	18	achievement.5	achievement.5	PROPN
ecj-10032	13	19	several	several	ADJ
ecj-10032	13	20	vaccination	vaccination	NOUN
ecj-10032	13	21	plans	plan	NOUN
ecj-10032	13	22	are	be	AUX
ecj-10032	13	23	currently	currently	ADV
ecj-10032	13	24	available	available	ADJ
ecj-10032	13	25	worldwide	worldwide	ADV
ecj-10032	13	26	.	.	PUNCT
ecj-10032	14	1	according	accord	VERB
ecj-10032	14	2	to	to	ADP
ecj-10032	14	3	the	the	DET
ecj-10032	14	4	portal	portal	NOUN
ecj-10032	14	5	our	our	PRON
ecj-10032	14	6	world	world	NOUN
ecj-10032	14	7	in	in	ADP
ecj-10032	14	8	data	datum	NOUN
ecj-10032	14	9	developed	develop	VERB
ecj-10032	14	10	by	by	ADP
ecj-10032	14	11	the	the	DET
ecj-10032	14	12	oxford	oxford	PROPN
ecj-10032	14	13	martin	martin	PROPN
ecj-10032	14	14	school	school	PROPN
ecj-10032	14	15	/	/	SYM
ecj-10032	14	16	university	university	PROPN
ecj-10032	14	17	of	of	ADP
ecj-10032	14	18	oxford	oxford	PROPN
ecj-10032	14	19	,	,	PUNCT
ecj-10032	14	20	as	as	ADP
ecj-10032	14	21	of	of	ADP
ecj-10032	14	22	october	october	PROPN
ecj-10032	14	23	26th	26th	NOUN
ecj-10032	14	24	2021	2021	NUM
ecj-10032	14	25	,	,	PUNCT
ecj-10032	14	26	48,7	48,7	NUM
ecj-10032	14	27	%	%	NOUN
ecj-10032	14	28	of	of	ADP
ecj-10032	14	29	the	the	DET
ecj-10032	14	30	world	world	NOUN
ecj-10032	14	31	’s	’s	PART
ecj-10032	14	32	population	population	NOUN
ecj-10032	14	33	has	have	AUX
ecj-10032	14	34	received	receive	VERB
ecj-10032	14	35	at	at	ADV
ecj-10032	14	36	least	least	ADV
ecj-10032	14	37	one	one	NUM
ecj-10032	14	38	dose	dose	NOUN
ecj-10032	14	39	of	of	ADP
ecj-10032	14	40	vaccine	vaccine	NOUN
ecj-10032	14	41	.	.	PUNCT
ecj-10032	15	1	data	datum	NOUN
ecj-10032	15	2	from	from	ADP
ecj-10032	15	3	the	the	DET
ecj-10032	15	4	italian	italian	ADJ
ecj-10032	15	5	government	government	NOUN
ecj-10032	15	6	health	health	PROPN
ecj-10032	15	7	ministry	ministry	PROPN
ecj-10032	15	8	report	report	VERB
ecj-10032	15	9	that	that	SCONJ
ecj-10032	15	10	in	in	ADP
ecj-10032	15	11	italy	italy	PROPN
ecj-10032	15	12	,	,	PUNCT
ecj-10032	15	13	86	86	NUM
ecj-10032	15	14	%	%	NOUN
ecj-10032	15	15	of	of	ADP
ecj-10032	15	16	the	the	DET
ecj-10032	15	17	population	population	NOUN
ecj-10032	15	18	over-12	over-12	PROPN
ecj-10032	15	19	has	have	AUX
ecj-10032	15	20	received	receive	VERB
ecj-10032	15	21	at	at	ADV
ecj-10032	15	22	least	least	ADV
ecj-10032	15	23	one	one	NUM
ecj-10032	15	24	dose	dose	NOUN
ecj-10032	15	25	of	of	ADP
ecj-10032	15	26	vaccine	vaccine	NOUN
ecj-10032	15	27	,	,	PUNCT
ecj-10032	15	28	and	and	CCONJ
ecj-10032	15	29	82	82	NUM
ecj-10032	15	30	%	%	NOUN
ecj-10032	15	31	completed	complete	VERB
ecj-10032	15	32	the	the	DET
ecj-10032	15	33	vaccination	vaccination	NOUN
ecj-10032	15	34	program	program	NOUN
ecj-10032	15	35	.	.	PUNCT
ecj-10032	16	1	the	the	DET
ecj-10032	16	2	efficiency	efficiency	NOUN
ecj-10032	16	3	and	and	CCONJ
ecj-10032	16	4	progress	progress	NOUN
ecj-10032	16	5	of	of	ADP
ecj-10032	16	6	the	the	DET
ecj-10032	16	7	vaccination	vaccination	NOUN
ecj-10032	16	8	campaign	campaign	NOUN
ecj-10032	16	9	rely	rely	VERB
ecj-10032	16	10	on	on	ADP
ecj-10032	16	11	the	the	DET
ecj-10032	16	12	different	different	ADJ
ecj-10032	16	13	vaccine	vaccine	NOUN
ecj-10032	16	14	’s	’s	PART
ecj-10032	16	15	availability	availability	NOUN
ecj-10032	16	16	and	and	CCONJ
ecj-10032	16	17	indications	indication	NOUN
ecj-10032	16	18	,	,	PUNCT
ecj-10032	16	19	as	as	SCONJ
ecj-10032	16	20	established	establish	VERB
ecj-10032	16	21	by	by	ADP
ecj-10032	16	22	the	the	DET
ecj-10032	16	23	european	european	PROPN
ecj-10032	16	24	medicines	medicines	PROPN
ecj-10032	16	25	agency	agency	NOUN
ecj-10032	16	26	(	(	PUNCT
ecj-10032	16	27	ema	ema	PROPN
ecj-10032	16	28	)	)	PUNCT
ecj-10032	16	29	.	.	PUNCT
ecj-10032	17	1	there	there	PRON
ecj-10032	17	2	are	be	VERB
ecj-10032	17	3	currently	currently	ADV
ecj-10032	17	4	four	four	NUM
ecj-10032	17	5	vaccines	vaccine	NOUN
ecj-10032	17	6	authorized	authorize	VERB
ecj-10032	17	7	and	and	CCONJ
ecj-10032	17	8	regulated	regulate	VERB
ecj-10032	17	9	for	for	ADP
ecj-10032	17	10	use	use	NOUN
ecj-10032	17	11	in	in	ADP
ecj-10032	17	12	europe	europe	PROPN
ecj-10032	17	13	.	.	PUNCT
ecj-10032	18	1	the	the	DET
ecj-10032	18	2	first	first	ADJ
ecj-10032	18	3	two	two	NUM
ecj-10032	18	4	,	,	PUNCT
ecj-10032	18	5	“	"	PUNCT
ecj-10032	18	6	bnt162b2	bnt162b2	NOUN
ecj-10032	18	7	”	"	PUNCT
ecj-10032	18	8	by	by	ADP
ecj-10032	18	9	pfizer	pfizer	NOUN
ecj-10032	18	10	/	/	SYM
ecj-10032	18	11	biontech	biontech	NOUN
ecj-10032	18	12	and	and	CCONJ
ecj-10032	18	13	“	"	PUNCT
ecj-10032	18	14	mrna-1273	mrna-1273	ADJ
ecj-10032	18	15	”	"	PUNCT
ecj-10032	18	16	by	by	ADP
ecj-10032	18	17	moderna	moderna	PROPN
ecj-10032	18	18	,	,	PUNCT
ecj-10032	18	19	rely	rely	VERB
ecj-10032	18	20	on	on	ADP
ecj-10032	18	21	an	an	DET
ecj-10032	18	22	innovative	innovative	ADJ
ecj-10032	18	23	mrna	mrna	NOUN
ecj-10032	18	24	technology	technology	NOUN
ecj-10032	18	25	encoding	encode	VERB
ecj-10032	18	26	for	for	ADP
ecj-10032	18	27	the	the	DET
ecj-10032	18	28	viral	viral	ADJ
ecj-10032	18	29	spike	spike	NOUN
ecj-10032	18	30	(	(	PUNCT
ecj-10032	18	31	s	s	NOUN
ecj-10032	18	32	)	)	PUNCT
ecj-10032	18	33	protein	protein	NOUN
ecj-10032	18	34	,	,	PUNCT
ecj-10032	18	35	encapsulated	encapsulate	VERB
ecj-10032	18	36	into	into	ADP
ecj-10032	18	37	lipid	lipid	ADJ
ecj-10032	18	38	nanoparticles	nanoparticle	NOUN
ecj-10032	18	39	.	.	PUNCT
ecj-10032	19	1	other	other	ADJ
ecj-10032	19	2	two	two	NUM
ecj-10032	19	3	correspondence	correspondence	NOUN
ecj-10032	19	4	:	:	PUNCT
ecj-10032	19	5	laura	laura	PROPN
ecj-10032	19	6	pini	pini	PROPN
ecj-10032	19	7	,	,	PUNCT
ecj-10032	19	8	respiratory	respiratory	ADJ
ecj-10032	19	9	medicine	medicine	NOUN
ecj-10032	19	10	unit	unit	NOUN
ecj-10032	19	11	,	,	PUNCT
ecj-10032	19	12	spedali	spedali	PROPN
ecj-10032	19	13	civili	civili	PROPN
ecj-10032	19	14	di	di	PROPN
ecj-10032	19	15	brescia	brescia	PROPN
ecj-10032	19	16	,	,	PUNCT
ecj-10032	19	17	department	department	NOUN
ecj-10032	19	18	of	of	ADP
ecj-10032	19	19	clinical	clinical	ADJ
ecj-10032	19	20	and	and	CCONJ
ecj-10032	19	21	experimental	experimental	ADJ
ecj-10032	19	22	sciences	science	NOUN
ecj-10032	19	23	,	,	PUNCT
ecj-10032	19	24	university	university	NOUN
ecj-10032	19	25	of	of	ADP
ecj-10032	19	26	brescia	brescia	PROPN
ecj-10032	19	27	,	,	PUNCT
ecj-10032	19	28	piazzale	piazzale	PROPN
ecj-10032	19	29	spedali	spedali	PROPN
ecj-10032	19	30	civili	civili	PROPN
ecj-10032	19	31	1	1	NUM
ecj-10032	19	32	,	,	PUNCT
ecj-10032	19	33	brescia	brescia	PROPN
ecj-10032	19	34	,	,	PUNCT
ecj-10032	19	35	italy	italy	PROPN
ecj-10032	19	36	.	.	PUNCT
ecj-10032	20	1	tel	tel	PROPN
ecj-10032	20	2	.	.	PUNCT
ecj-10032	20	3	:	:	PUNCT
ecj-10032	21	1	+39.(0)30.399.6263	+39.(0)30.399.6263	ADJ
ecj-10032	21	2	e	e	NOUN
ecj-10032	21	3	-	-	NOUN
ecj-10032	21	4	mail	mail	NOUN
ecj-10032	21	5	:	:	PUNCT
ecj-10032	21	6	laura.pini@unibs.it	laura.pini@unibs.it	PROPN
ecj-10032	21	7	key	key	ADJ
ecj-10032	21	8	words	word	NOUN
ecj-10032	21	9	:	:	PUNCT
ecj-10032	21	10	vaccine	vaccine	NOUN
ecj-10032	21	11	induced	induce	VERB
ecj-10032	21	12	thrombotic	thrombotic	ADJ
ecj-10032	21	13	thrombocytopenia	thrombocytopenia	PROPN
ecj-10032	21	14	;	;	PUNCT
ecj-10032	21	15	sarscov2	sarscov2	NOUN
ecj-10032	21	16	;	;	PUNCT
ecj-10032	21	17	covid-19	covid-19	PROPN
ecj-10032	21	18	vaccine	vaccine	NOUN
ecj-10032	21	19	;	;	PUNCT
ecj-10032	21	20	chadox1	chadox1	NOUN
ecj-10032	21	21	ncov-19	ncov-19	PROPN
ecj-10032	21	22	;	;	PUNCT
ecj-10032	21	23	astrazeneca	astrazeneca	PROPN
ecj-10032	21	24	.	.	PUNCT
ecj-10032	22	1	contributions	contribution	NOUN
ecj-10032	22	2	:	:	PUNCT
ecj-10032	22	3	lp	lp	NOUN
ecj-10032	22	4	and	and	CCONJ
ecj-10032	22	5	pm	pm	NOUN
ecj-10032	22	6	equally	equally	ADV
ecj-10032	22	7	contributed	contribute	VERB
ecj-10032	22	8	to	to	ADP
ecj-10032	22	9	this	this	DET
ecj-10032	22	10	paper	paper	NOUN
ecj-10032	22	11	.	.	PUNCT
ecj-10032	23	1	ca	can	AUX
ecj-10032	23	2	,	,	PUNCT
ecj-10032	23	3	lp	lp	ADJ
ecj-10032	23	4	,	,	PUNCT
ecj-10032	23	5	ds	ds	PROPN
ecj-10032	23	6	,	,	PUNCT
ecj-10032	23	7	gm	gm	PROPN
ecj-10032	23	8	,	,	PUNCT
ecj-10032	23	9	pm	pm	PROPN
ecj-10032	23	10	,	,	PUNCT
ecj-10032	23	11	ga	ga	PROPN
ecj-10032	23	12	,	,	PUNCT
ecj-10032	23	13	cp	cp	PROPN
ecj-10032	23	14	,	,	PUNCT
ecj-10032	23	15	gb	gb	PRON
ecj-10032	23	16	,	,	PUNCT
ecj-10032	23	17	ml	ml	NOUN
ecj-10032	23	18	,	,	PUNCT
ecj-10032	23	19	fb	fb	INTJ
ecj-10032	23	20	,	,	PUNCT
ecj-10032	23	21	gm	gm	PROPN
ecj-10032	23	22	:	:	PUNCT
ecj-10032	23	23	clinical	clinical	ADJ
ecj-10032	23	24	case	case	NOUN
ecj-10032	23	25	management	management	NOUN
ecj-10032	23	26	;	;	PUNCT
ecj-10032	23	27	pm	pm	NOUN
ecj-10032	23	28	,	,	PUNCT
ecj-10032	23	29	jg	jg	PROPN
ecj-10032	23	30	,	,	PUNCT
ecj-10032	23	31	pm	pm	PROPN
ecj-10032	23	32	,	,	PUNCT
ecj-10032	23	33	ga	ga	PROPN
ecj-10032	23	34	,	,	PUNCT
ecj-10032	23	35	cp	cp	PROPN
ecj-10032	23	36	,	,	PUNCT
ecj-10032	23	37	gb	gb	PRON
ecj-10032	23	38	,	,	PUNCT
ecj-10032	23	39	ml	ml	NOUN
ecj-10032	23	40	,	,	PUNCT
ecj-10032	23	41	fb	fb	INTJ
ecj-10032	23	42	,	,	PUNCT
ecj-10032	23	43	gm	gm	PROPN
ecj-10032	23	44	:	:	PUNCT
ecj-10032	23	45	clinical	clinical	ADJ
ecj-10032	23	46	data	datum	NOUN
ecj-10032	23	47	collection	collection	NOUN
ecj-10032	23	48	;	;	PUNCT
ecj-10032	23	49	pm	pm	NOUN
ecj-10032	23	50	,	,	PUNCT
ecj-10032	23	51	jg	jg	PROPN
ecj-10032	23	52	,	,	PUNCT
ecj-10032	23	53	ga	ga	PROPN
ecj-10032	23	54	:	:	PUNCT
ecj-10032	23	55	first	first	ADJ
ecj-10032	23	56	draft	draft	NOUN
ecj-10032	23	57	;	;	PUNCT
ecj-10032	23	58	mlm	mlm	NOUN
ecj-10032	23	59	:	:	PUNCT
ecj-10032	23	60	manuscript	manuscript	NOUN
ecj-10032	23	61	revision	revision	NOUN
ecj-10032	23	62	and	and	CCONJ
ecj-10032	23	63	chief	chief	NOUN
ecj-10032	23	64	of	of	ADP
ecj-10032	23	65	the	the	DET
ecj-10032	23	66	department	department	NOUN
ecj-10032	23	67	.	.	PUNCT
ecj-10032	24	1	conflict	conflict	NOUN
ecj-10032	24	2	of	of	ADP
ecj-10032	24	3	interests	interest	NOUN
ecj-10032	24	4	:	:	PUNCT
ecj-10032	24	5	the	the	DET
ecj-10032	24	6	authors	author	NOUN
ecj-10032	24	7	declare	declare	VERB
ecj-10032	24	8	no	no	DET
ecj-10032	24	9	conflict	conflict	NOUN
ecj-10032	24	10	of	of	ADP
ecj-10032	24	11	interest	interest	NOUN
ecj-10032	24	12	.	.	PUNCT
ecj-10032	25	1	availability	availability	NOUN
ecj-10032	25	2	of	of	ADP
ecj-10032	25	3	data	datum	NOUN
ecj-10032	25	4	and	and	CCONJ
ecj-10032	25	5	materials	material	NOUN
ecj-10032	25	6	:	:	PUNCT
ecj-10032	25	7	all	all	DET
ecj-10032	25	8	data	datum	NOUN
ecj-10032	25	9	underlying	underlie	VERB
ecj-10032	25	10	the	the	DET
ecj-10032	25	11	findings	finding	NOUN
ecj-10032	25	12	are	be	AUX
ecj-10032	25	13	fully	fully	ADV
ecj-10032	25	14	available	available	ADJ
ecj-10032	25	15	.	.	PUNCT
ecj-10032	26	1	ethics	ethic	NOUN
ecj-10032	26	2	approval	approval	NOUN
ecj-10032	26	3	and	and	CCONJ
ecj-10032	26	4	consent	consent	NOUN
ecj-10032	26	5	to	to	PART
ecj-10032	26	6	participate	participate	VERB
ecj-10032	26	7	:	:	PUNCT
ecj-10032	26	8	no	no	DET
ecj-10032	26	9	ethical	ethical	ADJ
ecj-10032	26	10	committee	committee	NOUN
ecj-10032	26	11	approval	approval	NOUN
ecj-10032	26	12	was	be	AUX
ecj-10032	26	13	required	require	VERB
ecj-10032	26	14	for	for	ADP
ecj-10032	26	15	this	this	DET
ecj-10032	26	16	case	case	NOUN
ecj-10032	26	17	report	report	NOUN
ecj-10032	26	18	by	by	ADP
ecj-10032	26	19	the	the	DET
ecj-10032	26	20	department	department	NOUN
ecj-10032	26	21	,	,	PUNCT
ecj-10032	26	22	because	because	SCONJ
ecj-10032	26	23	this	this	DET
ecj-10032	26	24	article	article	NOUN
ecj-10032	26	25	does	do	AUX
ecj-10032	26	26	not	not	PART
ecj-10032	26	27	contain	contain	VERB
ecj-10032	26	28	any	any	DET
ecj-10032	26	29	studies	study	NOUN
ecj-10032	26	30	with	with	ADP
ecj-10032	26	31	human	human	ADJ
ecj-10032	26	32	participants	participant	NOUN
ecj-10032	26	33	or	or	CCONJ
ecj-10032	26	34	animals	animal	NOUN
ecj-10032	26	35	.	.	PUNCT
ecj-10032	27	1	informed	inform	VERB
ecj-10032	27	2	consent	consent	NOUN
ecj-10032	27	3	was	be	AUX
ecj-10032	27	4	obtained	obtain	VERB
ecj-10032	27	5	from	from	ADP
ecj-10032	27	6	the	the	DET
ecj-10032	27	7	patient	patient	NOUN
ecj-10032	27	8	included	include	VERB
ecj-10032	27	9	in	in	ADP
ecj-10032	27	10	this	this	DET
ecj-10032	27	11	study	study	NOUN
ecj-10032	27	12	.	.	PUNCT
ecj-10032	28	1	consent	consent	NOUN
ecj-10032	28	2	for	for	ADP
ecj-10032	28	3	publication	publication	NOUN
ecj-10032	28	4	:	:	PUNCT
ecj-10032	28	5	the	the	DET
ecj-10032	28	6	patient	patient	NOUN
ecj-10032	28	7	gave	give	VERB
ecj-10032	28	8	her	she	PRON
ecj-10032	28	9	written	write	VERB
ecj-10032	28	10	consent	consent	NOUN
ecj-10032	28	11	to	to	PART
ecj-10032	28	12	use	use	VERB
ecj-10032	28	13	her	her	PRON
ecj-10032	28	14	personal	personal	ADJ
ecj-10032	28	15	data	datum	NOUN
ecj-10032	28	16	for	for	ADP
ecj-10032	28	17	the	the	DET
ecj-10032	28	18	publication	publication	NOUN
ecj-10032	28	19	of	of	ADP
ecj-10032	28	20	this	this	DET
ecj-10032	28	21	case	case	NOUN
ecj-10032	28	22	report	report	NOUN
ecj-10032	28	23	and	and	CCONJ
ecj-10032	28	24	any	any	DET
ecj-10032	28	25	accompanying	accompanying	ADJ
ecj-10032	28	26	images	image	NOUN
ecj-10032	28	27	.	.	PUNCT
ecj-10032	29	1	received	receive	VERB
ecj-10032	29	2	for	for	ADP
ecj-10032	29	3	publication	publication	NOUN
ecj-10032	29	4	:	:	PUNCT
ecj-10032	29	5	12	12	NUM
ecj-10032	29	6	august	august	PROPN
ecj-10032	29	7	2021	2021	NUM
ecj-10032	29	8	.	.	PUNCT
ecj-10032	30	1	revision	revision	NOUN
ecj-10032	30	2	received	receive	VERB
ecj-10032	30	3	:	:	PUNCT
ecj-10032	30	4	28	28	NUM
ecj-10032	30	5	october	october	PROPN
ecj-10032	30	6	2021	2021	NUM
ecj-10032	30	7	.	.	PUNCT
ecj-10032	31	1	accepted	accept	VERB
ecj-10032	31	2	for	for	ADP
ecj-10032	31	3	publication	publication	NOUN
ecj-10032	31	4	:	:	PUNCT
ecj-10032	31	5	9	9	NUM
ecj-10032	31	6	november	november	NOUN
ecj-10032	31	7	2021	2021	NUM
ecj-10032	31	8	.	.	PUNCT
ecj-10032	32	1	this	this	DET
ecj-10032	32	2	work	work	NOUN
ecj-10032	32	3	is	be	AUX
ecj-10032	32	4	licensed	license	VERB
ecj-10032	32	5	under	under	ADP
ecj-10032	32	6	a	a	DET
ecj-10032	32	7	creative	creative	ADJ
ecj-10032	32	8	commons	common	NOUN
ecj-10032	32	9	attribution	attribution	NOUN
ecj-10032	32	10	4.0	4.0	NUM
ecj-10032	32	11	license	license	NOUN
ecj-10032	32	12	(	(	PUNCT
ecj-10032	32	13	by	by	ADP
ecj-10032	32	14	-	-	PUNCT
ecj-10032	32	15	nc	nc	PROPN
ecj-10032	32	16	4.0	4.0	NUM
ecj-10032	32	17	)	)	PUNCT
ecj-10032	32	18	.	.	PUNCT
ecj-10032	33	1	©	©	PROPN
ecj-10032	33	2	copyright	copyright	NOUN
ecj-10032	33	3	:	:	PUNCT
ecj-10032	33	4	the	the	DET
ecj-10032	33	5	author(s	author(s	PROPN
ecj-10032	33	6	)	)	PUNCT
ecj-10032	33	7	,	,	PUNCT
ecj-10032	33	8	2021	2021	NUM
ecj-10032	33	9	licensee	licensee	NOUN
ecj-10032	33	10	pagepress	pagepress	NOUN
ecj-10032	33	11	,	,	PUNCT
ecj-10032	33	12	italy	italy	PROPN
ecj-10032	33	13	emergency	emergency	PROPN
ecj-10032	33	14	care	care	PROPN
ecj-10032	33	15	journal	journal	PROPN
ecj-10032	33	16	2021	2021	NUM
ecj-10032	33	17	;	;	PUNCT
ecj-10032	33	18	17:10032	17:10032	NUM
ecj-10032	33	19	doi:10.4081	doi:10.4081	NOUN
ecj-10032	33	20	/	/	SYM
ecj-10032	33	21	ecj.2021.10032	ecj.2021.10032	NUM
ecj-10032	33	22	a	a	DET
ecj-10032	33	23	case	case	NOUN
ecj-10032	33	24	of	of	ADP
ecj-10032	33	25	vaccine	vaccine	NOUN
ecj-10032	33	26	-	-	PUNCT
ecj-10032	33	27	induced	induce	VERB
ecj-10032	33	28	thrombotic	thrombotic	ADJ
ecj-10032	33	29	thrombocytopenia	thrombocytopenia	NOUN
ecj-10032	33	30	(	(	PUNCT
ecj-10032	33	31	vitt	vitt	PROPN
ecj-10032	33	32	)	)	PUNCT
ecj-10032	33	33	with	with	ADP
ecj-10032	33	34	thrombosis	thrombosis	NOUN
ecj-10032	33	35	of	of	ADP
ecj-10032	33	36	the	the	DET
ecj-10032	33	37	superior	superior	ADJ
ecj-10032	33	38	mesenteric	mesenteric	ADJ
ecj-10032	33	39	artery	artery	NOUN
ecj-10032	33	40	after	after	ADP
ecj-10032	33	41	chadox1	chadox1	NOUN
ecj-10032	33	42	ncov-19	ncov-19	PROPN
ecj-10032	33	43	covid-19	covid-19	PROPN
ecj-10032	33	44	vaccine	vaccine	NOUN
ecj-10032	33	45	laura	laura	NOUN
ecj-10032	33	46	pini,1,2	pini,1,2	PROPN
ecj-10032	33	47	*	*	PROPN
ecj-10032	33	48	paolo	paolo	PROPN
ecj-10032	33	49	malerba,2,3	malerba,2,3	PROPN
ecj-10032	33	50	*	*	PROPN
ecj-10032	33	51	jordan	jordan	PROPN
ecj-10032	33	52	giordani,1	giordani,1	PROPN
ecj-10032	33	53	deborah	deborah	PROPN
ecj-10032	33	54	stassaldi,2	stassaldi,2	PROPN
ecj-10032	33	55	carlo	carlo	PROPN
ecj-10032	33	56	aggiusti,2	aggiusti,2	PROPN
ecj-10032	33	57	giuliana	giuliana	PROPN
ecj-10032	33	58	martini,4	martini,4	VERB
ecj-10032	33	59	giulia	giulia	PROPN
ecj-10032	33	60	arenare,2,3	arenare,2,3	ADJ
ecj-10032	33	61	chantale	chantale	NOUN
ecj-10032	33	62	premoli,2,5	premoli,2,5	PROPN
ecj-10032	33	63	giulia	giulia	PROPN
ecj-10032	33	64	bosio,2,5	bosio,2,5	PROPN
ecj-10032	33	65	marco	marco	PROPN
ecj-10032	33	66	lancelotti,2,5	lancelotti,2,5	PROPN
ecj-10032	33	67	francesca	francesca	PROPN
ecj-10032	33	68	bosisio,2,5	bosisio,2,5	PROPN
ecj-10032	33	69	giorgia	giorgia	PROPN
ecj-10032	33	70	muzi,2,5	muzi,2,5	PROPN
ecj-10032	33	71	maria	maria	PROPN
ecj-10032	33	72	lorenza	lorenza	ADJ
ecj-10032	33	73	muiesan2	muiesan2	NOUN
ecj-10032	34	1	1respiratory	1respiratory	NUM
ecj-10032	34	2	medicine	medicine	NOUN
ecj-10032	34	3	unit	unit	NOUN
ecj-10032	34	4	;	;	PUNCT
ecj-10032	34	5	2uoc	2uoc	PROPN
ecj-10032	34	6	2a	2a	NUM
ecj-10032	34	7	medicina	medicina	PROPN
ecj-10032	34	8	,	,	PUNCT
ecj-10032	34	9	spedali	spedali	PROPN
ecj-10032	34	10	civili	civili	PROPN
ecj-10032	34	11	di	di	PROPN
ecj-10032	34	12	brescia	brescia	PROPN
ecj-10032	34	13	,	,	PUNCT
ecj-10032	34	14	department	department	NOUN
ecj-10032	34	15	of	of	ADP
ecj-10032	34	16	clinical	clinical	ADJ
ecj-10032	34	17	and	and	CCONJ
ecj-10032	34	18	experimental	experimental	ADJ
ecj-10032	34	19	sciences	science	NOUN
ecj-10032	34	20	,	,	PUNCT
ecj-10032	34	21	university	university	NOUN
ecj-10032	34	22	of	of	ADP
ecj-10032	34	23	brescia	brescia	PROPN
ecj-10032	34	24	,	,	PUNCT
ecj-10032	34	25	brescia	brescia	PROPN
ecj-10032	34	26	;	;	PUNCT
ecj-10032	34	27	3post	3post	NUM
ecj-10032	34	28	-	-	ADJ
ecj-10032	34	29	graduate	graduate	ADJ
ecj-10032	34	30	school	school	NOUN
ecj-10032	34	31	of	of	ADP
ecj-10032	34	32	internal	internal	ADJ
ecj-10032	34	33	medicine	medicine	NOUN
ecj-10032	34	34	,	,	PUNCT
ecj-10032	34	35	university	university	NOUN
ecj-10032	34	36	of	of	ADP
ecj-10032	34	37	brescia	brescia	PROPN
ecj-10032	34	38	,	,	PUNCT
ecj-10032	34	39	brescia	brescia	PROPN
ecj-10032	34	40	;	;	PUNCT
ecj-10032	34	41	4hemostasis	4hemostasis	NUM
ecj-10032	34	42	central	central	ADJ
ecj-10032	34	43	laboratory	laboratory	NOUN
ecj-10032	34	44	,	,	PUNCT
ecj-10032	34	45	asst	asst	PROPN
ecj-10032	34	46	spedali	spedali	PROPN
ecj-10032	34	47	civili	civili	PROPN
ecj-10032	34	48	of	of	ADP
ecj-10032	34	49	brescia	brescia	PROPN
ecj-10032	34	50	,	,	PUNCT
ecj-10032	34	51	brescia	brescia	PROPN
ecj-10032	34	52	;	;	PUNCT
ecj-10032	34	53	5post	5post	NUM
ecj-10032	34	54	-	-	PUNCT
ecj-10032	34	55	graduate	graduate	ADJ
ecj-10032	34	56	school	school	NOUN
ecj-10032	34	57	of	of	ADP
ecj-10032	34	58	emergency	emergency	NOUN
ecj-10032	34	59	medicine	medicine	NOUN
ecj-10032	34	60	,	,	PUNCT
ecj-10032	34	61	university	university	NOUN
ecj-10032	34	62	of	of	ADP
ecj-10032	34	63	brescia	brescia	PROPN
ecj-10032	34	64	,	,	PUNCT
ecj-10032	34	65	brescia	brescia	PROPN
ecj-10032	34	66	,	,	PUNCT
ecj-10032	34	67	italy	italy	PROPN
ecj-10032	34	68	non	non	PROPN
ecj-10032	34	69	-co	-co	PROPN
ecj-10032	34	70	mmerc	mmerc	PROPN
ecj-10032	34	71	ial	ial	PROPN
ecj-10032	34	72	us	us	PROPN
ecj-10032	34	73	e	e	NOUN
ecj-10032	34	74	o	o	NOUN
ecj-10032	34	75	nly	nly	ADV
ecj-10032	34	76	vaccines	vaccine	NOUN
ecj-10032	34	77	,	,	PUNCT
ecj-10032	34	78	astrazeneca	astrazeneca	PROPN
ecj-10032	34	79	’s	’s	PART
ecj-10032	34	80	chadox1	chadox1	NOUN
ecj-10032	34	81	ncov-19	ncov-19	PROPN
ecj-10032	34	82	and	and	CCONJ
ecj-10032	34	83	johnson	johnson	PROPN
ecj-10032	34	84	&	&	CCONJ
ecj-10032	34	85	johnson	johnson	PROPN
ecj-10032	34	86	/	/	SYM
ecj-10032	34	87	janssen	janssen	PROPN
ecj-10032	34	88	’s	’s	PART
ecj-10032	34	89	ad26.cov.2	ad26.cov.2	NOUN
ecj-10032	34	90	are	be	AUX
ecj-10032	34	91	based	base	VERB
ecj-10032	34	92	on	on	ADP
ecj-10032	34	93	an	an	DET
ecj-10032	34	94	adenoviral	adenoviral	ADJ
ecj-10032	34	95	vector	vector	NOUN
ecj-10032	34	96	codifying	codify	VERB
ecj-10032	34	97	for	for	ADP
ecj-10032	34	98	the	the	DET
ecj-10032	34	99	spike	spike	ADJ
ecj-10032	34	100	protein	protein	NOUN
ecj-10032	34	101	antigen.6	antigen.6	NOUN
ecj-10032	34	102	like	like	ADP
ecj-10032	34	103	any	any	DET
ecj-10032	34	104	drug	drug	NOUN
ecj-10032	34	105	,	,	PUNCT
ecj-10032	34	106	sars	sars	PROPN
ecj-10032	34	107	-	-	PUNCT
ecj-10032	34	108	cov2	cov2	PROPN
ecj-10032	34	109	vaccines	vaccine	NOUN
ecj-10032	34	110	have	have	VERB
ecj-10032	34	111	different	different	ADJ
ecj-10032	34	112	side	side	NOUN
ecj-10032	34	113	effects	effect	NOUN
ecj-10032	34	114	,	,	PUNCT
ecj-10032	34	115	with	with	ADP
ecj-10032	34	116	pain	pain	NOUN
ecj-10032	34	117	at	at	ADP
ecj-10032	34	118	the	the	DET
ecj-10032	34	119	injection	injection	NOUN
ecj-10032	34	120	site	site	NOUN
ecj-10032	34	121	,	,	PUNCT
ecj-10032	34	122	polyarthralgia	polyarthralgia	NOUN
ecj-10032	34	123	,	,	PUNCT
ecj-10032	34	124	fever	fever	NOUN
ecj-10032	34	125	with	with	ADP
ecj-10032	34	126	chills	chill	NOUN
ecj-10032	34	127	,	,	PUNCT
ecj-10032	34	128	fatigue	fatigue	NOUN
ecj-10032	34	129	and	and	CCONJ
ecj-10032	34	130	gastrointestinal	gastrointestinal	ADJ
ecj-10032	34	131	symptoms	symptom	NOUN
ecj-10032	34	132	occurring	occur	VERB
ecj-10032	34	133	most	most	ADV
ecj-10032	34	134	frequently.7	frequently.7	NOUN
ecj-10032	34	135	in	in	ADP
ecj-10032	34	136	this	this	DET
ecj-10032	34	137	context	context	NOUN
ecj-10032	34	138	,	,	PUNCT
ecj-10032	34	139	there	there	PRON
ecj-10032	34	140	have	have	AUX
ecj-10032	34	141	been	be	AUX
ecj-10032	34	142	heated	heat	VERB
ecj-10032	34	143	discussions	discussion	NOUN
ecj-10032	34	144	and	and	CCONJ
ecj-10032	34	145	controversial	controversial	ADJ
ecj-10032	34	146	arguments	argument	NOUN
ecj-10032	34	147	due	due	ADP
ecj-10032	34	148	to	to	ADP
ecj-10032	34	149	the	the	DET
ecj-10032	34	150	occurrence	occurrence	NOUN
ecj-10032	34	151	of	of	ADP
ecj-10032	34	152	thromboembolic	thromboembolic	ADJ
ecj-10032	34	153	events	event	NOUN
ecj-10032	34	154	following	follow	VERB
ecj-10032	34	155	the	the	DET
ecj-10032	34	156	administration	administration	NOUN
ecj-10032	34	157	of	of	ADP
ecj-10032	34	158	chadox1	chadox1	NOUN
ecj-10032	34	159	ncov-19	ncov-19	PROPN
ecj-10032	34	160	and	and	CCONJ
ecj-10032	34	161	ad26.cov.2	ad26.cov.2	VERB
ecj-10032	34	162	vaccines.8,9	vaccines.8,9	ADP
ecj-10032	34	163	this	this	DET
ecj-10032	34	164	paper	paper	NOUN
ecj-10032	34	165	reports	report	VERB
ecj-10032	34	166	a	a	DET
ecj-10032	34	167	clinical	clinical	ADJ
ecj-10032	34	168	case	case	NOUN
ecj-10032	34	169	of	of	ADP
ecj-10032	34	170	a	a	DET
ecj-10032	34	171	vaccine	vaccine	NOUN
ecj-10032	34	172	-	-	PUNCT
ecj-10032	34	173	induced	induce	VERB
ecj-10032	34	174	thrombocytopenic	thrombocytopenic	ADJ
ecj-10032	34	175	thrombosis	thrombosis	NOUN
ecj-10032	34	176	(	(	PUNCT
ecj-10032	34	177	vitt	vitt	PROPN
ecj-10032	34	178	)	)	PUNCT
ecj-10032	34	179	involving	involve	VERB
ecj-10032	34	180	the	the	DET
ecj-10032	34	181	superior	superior	ADJ
ecj-10032	34	182	mesenteric	mesenteric	ADJ
ecj-10032	34	183	artery	artery	NOUN
ecj-10032	34	184	in	in	ADP
ecj-10032	34	185	a	a	DET
ecj-10032	34	186	64	64	NUM
ecj-10032	34	187	-	-	PUNCT
ecj-10032	34	188	year	year	NOUN
ecj-10032	34	189	-	-	PUNCT
ecj-10032	34	190	old	old	ADJ
ecj-10032	34	191	woman	woman	NOUN
ecj-10032	34	192	who	who	PRON
ecj-10032	34	193	received	receive	VERB
ecj-10032	34	194	the	the	DET
ecj-10032	34	195	first	first	ADJ
ecj-10032	34	196	dose	dose	NOUN
ecj-10032	34	197	of	of	ADP
ecj-10032	34	198	chadox1	chadox1	ADJ
ecj-10032	34	199	ncov-19	ncov-19	PROPN
ecj-10032	34	200	vaccine	vaccine	NOUN
ecj-10032	34	201	10	10	NUM
ecj-10032	34	202	days	day	NOUN
ecj-10032	34	203	before	before	ADP
ecj-10032	34	204	admission	admission	NOUN
ecj-10032	34	205	.	.	PUNCT
ecj-10032	35	1	case	case	NOUN
ecj-10032	35	2	report	report	VERB
ecj-10032	35	3	a	a	DET
ecj-10032	35	4	64	64	NUM
ecj-10032	35	5	years	year	NOUN
ecj-10032	35	6	-	-	PUNCT
ecj-10032	35	7	old	old	ADJ
ecj-10032	35	8	woman	woman	NOUN
ecj-10032	35	9	was	be	AUX
ecj-10032	35	10	admitted	admit	VERB
ecj-10032	35	11	on	on	ADP
ecj-10032	35	12	may	may	PROPN
ecj-10032	35	13	10th	10th	NUM
ecj-10032	35	14	,	,	PUNCT
ecj-10032	35	15	2021	2021	NUM
ecj-10032	35	16	to	to	ADP
ecj-10032	35	17	the	the	DET
ecj-10032	35	18	emergency	emergency	NOUN
ecj-10032	35	19	department	department	NOUN
ecj-10032	35	20	(	(	PUNCT
ecj-10032	35	21	ed	ed	NOUN
ecj-10032	35	22	)	)	PUNCT
ecj-10032	35	23	of	of	ADP
ecj-10032	35	24	the	the	DET
ecj-10032	35	25	asst	asst	NOUN
ecj-10032	35	26	-	-	PUNCT
ecj-10032	35	27	spedali	spedali	PROPN
ecj-10032	35	28	civili	civili	PROPN
ecj-10032	35	29	in	in	ADP
ecj-10032	35	30	brescia	brescia	PROPN
ecj-10032	35	31	(	(	PUNCT
ecj-10032	35	32	northern	northern	PROPN
ecj-10032	35	33	italy	italy	PROPN
ecj-10032	35	34	)	)	PUNCT
ecj-10032	35	35	,	,	PUNCT
ecj-10032	35	36	complaining	complain	VERB
ecj-10032	35	37	of	of	ADP
ecj-10032	35	38	fever	fever	NOUN
ecj-10032	35	39	(	(	PUNCT
ecj-10032	35	40	t	t	PROPN
ecj-10032	35	41	max	max	PROPN
ecj-10032	35	42	38	38	NUM
ecj-10032	35	43	°	°	PROPN
ecj-10032	35	44	c	c	NOUN
ecj-10032	35	45	)	)	PUNCT
ecj-10032	35	46	,	,	PUNCT
ecj-10032	35	47	fatigue	fatigue	NOUN
ecj-10032	35	48	,	,	PUNCT
ecj-10032	35	49	abdominal	abdominal	ADJ
ecj-10032	35	50	pain	pain	NOUN
ecj-10032	35	51	,	,	PUNCT
ecj-10032	35	52	vomiting	vomit	VERB
ecj-10032	35	53	unresponsive	unresponsive	ADJ
ecj-10032	35	54	to	to	ADP
ecj-10032	35	55	metoclopramide	metoclopramide	NOUN
ecj-10032	35	56	,	,	PUNCT
ecj-10032	35	57	and	and	CCONJ
ecj-10032	35	58	diarrhea	diarrhea	NOUN
ecj-10032	35	59	(	(	PUNCT
ecj-10032	35	60	5	5	NUM
ecj-10032	35	61	-	-	SYM
ecj-10032	35	62	6	6	NUM
ecj-10032	35	63	episodes	episode	NOUN
ecj-10032	35	64	/	/	SYM
ecj-10032	35	65	day	day	NOUN
ecj-10032	35	66	)	)	PUNCT
ecj-10032	35	67	.	.	PUNCT
ecj-10032	36	1	she	she	PRON
ecj-10032	36	2	had	have	AUX
ecj-10032	36	3	received	receive	VERB
ecj-10032	36	4	the	the	DET
ecj-10032	36	5	first	first	ADJ
ecj-10032	36	6	dose	dose	NOUN
ecj-10032	36	7	of	of	ADP
ecj-10032	36	8	chadox1	chadox1	NOUN
ecj-10032	36	9	ncov-19	ncov-19	PROPN
ecj-10032	36	10	,	,	PUNCT
ecj-10032	36	11	astrazeneca	astrazeneca	NOUN
ecj-10032	36	12	vaccine	vaccine	NOUN
ecj-10032	36	13	against	against	ADP
ecj-10032	36	14	sars	sar	NOUN
ecj-10032	36	15	-	-	PUNCT
ecj-10032	36	16	cov2	cov2	PROPN
ecj-10032	36	17	,	,	PUNCT
ecj-10032	36	18	on	on	ADP
ecj-10032	36	19	april	april	PROPN
ecj-10032	36	20	30th	30th	NUM
ecj-10032	36	21	.	.	PUNCT
ecj-10032	37	1	her	her	PRON
ecj-10032	37	2	past	past	ADJ
ecj-10032	37	3	medical	medical	ADJ
ecj-10032	37	4	history	history	NOUN
ecj-10032	37	5	included	include	VERB
ecj-10032	37	6	hypercholesterolemia	hypercholesterolemia	NOUN
ecj-10032	37	7	in	in	ADP
ecj-10032	37	8	treatment	treatment	NOUN
ecj-10032	37	9	with	with	ADP
ecj-10032	37	10	statins	statin	NOUN
ecj-10032	37	11	and	and	CCONJ
ecj-10032	37	12	gastro	gastro	NOUN
ecj-10032	37	13	-	-	PUNCT
ecj-10032	37	14	esophageal	esophageal	ADJ
ecj-10032	37	15	reflux	reflux	NOUN
ecj-10032	37	16	disease	disease	NOUN
ecj-10032	37	17	,	,	PUNCT
ecj-10032	37	18	and	and	CCONJ
ecj-10032	37	19	she	she	PRON
ecj-10032	37	20	did	do	AUX
ecj-10032	37	21	not	not	PART
ecj-10032	37	22	report	report	VERB
ecj-10032	37	23	personal	personal	ADJ
ecj-10032	37	24	or	or	CCONJ
ecj-10032	37	25	family	family	NOUN
ecj-10032	37	26	history	history	NOUN
ecj-10032	37	27	of	of	ADP
ecj-10032	37	28	venous	venous	ADJ
ecj-10032	37	29	thromboembolism	thromboembolism	NOUN
ecj-10032	37	30	.	.	PUNCT
ecj-10032	38	1	clinical	clinical	ADJ
ecj-10032	38	2	parameters	parameter	NOUN
ecj-10032	38	3	at	at	ADP
ecj-10032	38	4	ed	ed	PROPN
ecj-10032	38	5	arrival	arrival	NOUN
ecj-10032	38	6	were	be	AUX
ecj-10032	38	7	:	:	PUNCT
ecj-10032	38	8	heart	heart	NOUN
ecj-10032	38	9	rate	rate	NOUN
ecj-10032	38	10	(	(	PUNCT
ecj-10032	38	11	hr	hr	NOUN
ecj-10032	38	12	)	)	PUNCT
ecj-10032	38	13	55	55	NUM
ecj-10032	38	14	bpm	bpm	NOUN
ecj-10032	38	15	,	,	PUNCT
ecj-10032	38	16	blood	blood	NOUN
ecj-10032	38	17	pressure	pressure	NOUN
ecj-10032	38	18	(	(	PUNCT
ecj-10032	38	19	bp	bp	PROPN
ecj-10032	38	20	)	)	PUNCT
ecj-10032	38	21	180/85	180/85	NUM
ecj-10032	38	22	mmhg	mmhg	NOUN
ecj-10032	38	23	,	,	PUNCT
ecj-10032	38	24	peripheral	peripheral	ADJ
ecj-10032	38	25	arterial	arterial	ADJ
ecj-10032	38	26	oxygen	oxygen	NOUN
ecj-10032	38	27	saturation	saturation	NOUN
ecj-10032	38	28	(	(	PUNCT
ecj-10032	38	29	spo2	spo2	PROPN
ecj-10032	38	30	)	)	PUNCT
ecj-10032	38	31	99	99	NUM
ecj-10032	38	32	%	%	NOUN
ecj-10032	38	33	and	and	CCONJ
ecj-10032	38	34	tympanic	tympanic	NOUN
ecj-10032	38	35	temperature	temperature	NOUN
ecj-10032	38	36	35.5	35.5	NUM
ecj-10032	38	37	°	°	SYM
ecj-10032	38	38	c	c	NOUN
ecj-10032	38	39	.	.	PUNCT
ecj-10032	39	1	clinical	clinical	ADJ
ecj-10032	39	2	evaluation	evaluation	NOUN
ecj-10032	39	3	showed	show	VERB
ecj-10032	39	4	a	a	DET
ecj-10032	39	5	glasgow	glasgow	ADJ
ecj-10032	39	6	coma	coma	NOUN
ecj-10032	39	7	scale	scale	NOUN
ecj-10032	39	8	(	(	PUNCT
ecj-10032	39	9	gcs	gcs	PROPN
ecj-10032	39	10	)	)	PUNCT
ecj-10032	39	11	value	value	NOUN
ecj-10032	39	12	of	of	ADP
ecj-10032	39	13	15	15	NUM
ecj-10032	39	14	without	without	ADP
ecj-10032	39	15	other	other	ADJ
ecj-10032	39	16	significant	significant	ADJ
ecj-10032	39	17	clinical	clinical	ADJ
ecj-10032	39	18	or	or	CCONJ
ecj-10032	39	19	neurological	neurological	ADJ
ecj-10032	39	20	findings	finding	NOUN
ecj-10032	39	21	.	.	PUNCT
ecj-10032	40	1	laboratory	laboratory	NOUN
ecj-10032	40	2	investigations	investigation	NOUN
ecj-10032	40	3	showed	show	VERB
ecj-10032	40	4	leukocytosis	leukocytosis	NOUN
ecj-10032	40	5	(	(	PUNCT
ecj-10032	40	6	12.57x103/µl	12.57x103/µl	NUM
ecj-10032	40	7	)	)	PUNCT
ecj-10032	40	8	with	with	ADP
ecj-10032	40	9	neutrophilia	neutrophilia	PROPN
ecj-10032	40	10	(	(	PUNCT
ecj-10032	40	11	10.44x103/µl	10.44x103/µl	NUM
ecj-10032	40	12	)	)	PUNCT
ecj-10032	40	13	,	,	PUNCT
ecj-10032	40	14	thrombocytopenia	thrombocytopenia	PROPN
ecj-10032	40	15	(	(	PUNCT
ecj-10032	40	16	45.000/µl	45.000/µl	NUM
ecj-10032	40	17	)	)	PUNCT
ecj-10032	40	18	,	,	PUNCT
ecj-10032	40	19	mild	mild	ADJ
ecj-10032	40	20	hypokalemia	hypokalemia	NOUN
ecj-10032	40	21	(	(	PUNCT
ecj-10032	40	22	3.0mmol	3.0mmol	NOUN
ecj-10032	40	23	/	/	SYM
ecj-10032	40	24	l	l	NOUN
ecj-10032	40	25	)	)	PUNCT
ecj-10032	40	26	and	and	CCONJ
ecj-10032	40	27	a	a	DET
ecj-10032	40	28	mild	mild	ADJ
ecj-10032	40	29	increase	increase	NOUN
ecj-10032	40	30	in	in	ADP
ecj-10032	40	31	hepatic	hepatic	ADJ
ecj-10032	40	32	(	(	PUNCT
ecj-10032	40	33	ldh	ldh	PROPN
ecj-10032	40	34	:	:	PUNCT
ecj-10032	40	35	315u	315u	PROPN
ecj-10032	40	36	/	/	SYM
ecj-10032	40	37	l	l	PROPN
ecj-10032	40	38	–	–	PUNCT
ecj-10032	40	39	ast	ast	ADV
ecj-10032	40	40	:	:	PUNCT
ecj-10032	40	41	49u	49u	NUM
ecj-10032	40	42	/	/	SYM
ecj-10032	40	43	l	l	NOUN
ecj-10032	40	44	)	)	PUNCT
ecj-10032	40	45	and	and	CCONJ
ecj-10032	40	46	systemic	systemic	ADJ
ecj-10032	40	47	inflammatory	inflammatory	ADJ
ecj-10032	40	48	indexes	index	NOUN
ecj-10032	40	49	(	(	PUNCT
ecj-10032	40	50	crp	crp	NOUN
ecj-10032	40	51	:	:	PUNCT
ecj-10032	40	52	17.6mg	17.6mg	NUM
ecj-10032	40	53	/	/	SYM
ecj-10032	40	54	l	l	NOUN
ecj-10032	40	55	ferritin	ferritin	NOUN
ecj-10032	40	56	:	:	PUNCT
ecj-10032	40	57	198ug	198ug	PROPN
ecj-10032	40	58	/	/	SYM
ecj-10032	40	59	l	l	NOUN
ecj-10032	40	60	)	)	PUNCT
ecj-10032	40	61	.	.	PUNCT
ecj-10032	41	1	pt	pt	PROPN
ecj-10032	41	2	was	be	AUX
ecj-10032	41	3	13.3sec	13.3sec	NUM
ecj-10032	41	4	,	,	PUNCT
ecj-10032	41	5	pt	pt	PROPN
ecj-10032	41	6	ratio	ratio	NOUN
ecj-10032	41	7	1.1	1.1	NUM
ecj-10032	41	8	,	,	PUNCT
ecj-10032	41	9	aptt	aptt	PROPN
ecj-10032	41	10	24.3sec	24.3sec	PROPN
ecj-10032	41	11	,	,	PUNCT
ecj-10032	41	12	aptt	aptt	ADJ
ecj-10032	41	13	ratio	ratio	NOUN
ecj-10032	41	14	0.79	0.79	NUM
ecj-10032	41	15	with	with	ADP
ecj-10032	41	16	fibrinogen	fibrinogen	PROPN
ecj-10032	41	17	81mg	81mg	PROPN
ecj-10032	41	18	/	/	SYM
ecj-10032	41	19	dl	dl	PROPN
ecj-10032	41	20	and	and	CCONJ
ecj-10032	41	21	a	a	DET
ecj-10032	41	22	marked	mark	VERB
ecj-10032	41	23	increase	increase	NOUN
ecj-10032	41	24	in	in	ADP
ecj-10032	41	25	d	d	NOUN
ecj-10032	41	26	-	-	PUNCT
ecj-10032	41	27	dimer	dimer	NOUN
ecj-10032	41	28	(	(	PUNCT
ecj-10032	41	29	˃	˃	NOUN
ecj-10032	41	30	35000ng	35000ng	NOUN
ecj-10032	41	31	/	/	SYM
ecj-10032	41	32	ml	ml	NOUN
ecj-10032	41	33	)	)	PUNCT
ecj-10032	41	34	.	.	PUNCT
ecj-10032	42	1	a	a	DET
ecj-10032	42	2	nasopharyngeal	nasopharyngeal	ADJ
ecj-10032	42	3	swab	swab	NOUN
ecj-10032	42	4	for	for	ADP
ecj-10032	42	5	sars	sar	NOUN
ecj-10032	42	6	-	-	PUNCT
ecj-10032	42	7	cov2	cov2	PROPN
ecj-10032	42	8	infection	infection	NOUN
ecj-10032	42	9	tested	test	VERB
ecj-10032	42	10	negative	negative	ADJ
ecj-10032	42	11	.	.	PUNCT
ecj-10032	43	1	while	while	SCONJ
ecj-10032	43	2	in	in	ADP
ecj-10032	43	3	the	the	DET
ecj-10032	43	4	ed	ed	NOUN
ecj-10032	43	5	,	,	PUNCT
ecj-10032	43	6	the	the	DET
ecj-10032	43	7	patient	patient	NOUN
ecj-10032	43	8	complained	complain	VERB
ecj-10032	43	9	of	of	ADP
ecj-10032	43	10	a	a	DET
ecj-10032	43	11	minor	minor	ADJ
ecj-10032	43	12	episode	episode	NOUN
ecj-10032	43	13	of	of	ADP
ecj-10032	43	14	hematemesis	hematemesis	NOUN
ecj-10032	43	15	with	with	ADP
ecj-10032	43	16	rapid	rapid	ADJ
ecj-10032	43	17	resolution	resolution	NOUN
ecj-10032	43	18	.	.	PUNCT
ecj-10032	44	1	a	a	DET
ecj-10032	44	2	whole	whole	ADJ
ecj-10032	44	3	brain	brain	NOUN
ecj-10032	44	4	,	,	PUNCT
ecj-10032	44	5	chest	chest	NOUN
ecj-10032	44	6	,	,	PUNCT
ecj-10032	44	7	and	and	CCONJ
ecj-10032	44	8	abdomen	abdomen	VERB
ecj-10032	44	9	computerized	computerized	ADJ
ecj-10032	44	10	tomography	tomography	NOUN
ecj-10032	44	11	(	(	PUNCT
ecj-10032	44	12	ct)-scan	ct)-scan	VERB
ecj-10032	44	13	with	with	ADP
ecj-10032	44	14	and	and	CCONJ
ecj-10032	44	15	without	without	ADP
ecj-10032	44	16	contrast	contrast	NOUN
ecj-10032	44	17	medium	medium	NOUN
ecj-10032	44	18	(	(	PUNCT
ecj-10032	44	19	lopamidol	lopamidol	NOUN
ecj-10032	44	20	370	370	NUM
ecj-10032	44	21	,	,	PUNCT
ecj-10032	44	22	110ml	110ml	PROPN
ecj-10032	44	23	)	)	PUNCT
ecj-10032	44	24	was	be	AUX
ecj-10032	44	25	then	then	ADV
ecj-10032	44	26	performed	perform	VERB
ecj-10032	44	27	.	.	PUNCT
ecj-10032	45	1	ct	ct	PROPN
ecj-10032	45	2	scan	scan	NOUN
ecj-10032	45	3	of	of	ADP
ecj-10032	45	4	the	the	DET
ecj-10032	45	5	brain	brain	NOUN
ecj-10032	45	6	and	and	CCONJ
ecj-10032	45	7	chest	chest	NOUN
ecj-10032	45	8	did	do	AUX
ecj-10032	45	9	not	not	PART
ecj-10032	45	10	highlight	highlight	VERB
ecj-10032	45	11	any	any	DET
ecj-10032	45	12	significant	significant	ADJ
ecj-10032	45	13	finding	finding	NOUN
ecj-10032	45	14	and	and	CCONJ
ecj-10032	45	15	excluded	exclude	VERB
ecj-10032	45	16	the	the	DET
ecj-10032	45	17	presence	presence	NOUN
ecj-10032	45	18	of	of	ADP
ecj-10032	45	19	pulmonary	pulmonary	ADJ
ecj-10032	45	20	embolism	embolism	NOUN
ecj-10032	45	21	,	,	PUNCT
ecj-10032	45	22	while	while	SCONJ
ecj-10032	45	23	abdominal	abdominal	ADJ
ecj-10032	45	24	scans	scan	NOUN
ecj-10032	45	25	indicated	indicate	VERB
ecj-10032	45	26	a	a	PRON
ecj-10032	45	27	2	2	NUM
ecj-10032	45	28	cm	cm	NOUN
ecj-10032	45	29	long	long	ADV
ecj-10032	45	30	partially	partially	ADV
ecj-10032	45	31	occluding	occlude	VERB
ecj-10032	45	32	thrombosis	thrombosis	NOUN
ecj-10032	45	33	of	of	ADP
ecj-10032	45	34	the	the	DET
ecj-10032	45	35	superior	superior	ADJ
ecj-10032	45	36	mesenteric	mesenteric	ADJ
ecj-10032	45	37	artery	artery	NOUN
ecj-10032	45	38	,	,	PUNCT
ecj-10032	45	39	with	with	ADP
ecj-10032	45	40	local	local	ADJ
ecj-10032	45	41	thickening	thickening	NOUN
ecj-10032	45	42	and	and	CCONJ
ecj-10032	45	43	hyperemia	hyperemia	NOUN
ecj-10032	45	44	of	of	ADP
ecj-10032	45	45	small	small	ADJ
ecj-10032	45	46	intestine	intestine	NOUN
ecj-10032	45	47	loops	loop	NOUN
ecj-10032	45	48	(	(	PUNCT
ecj-10032	45	49	figure	figure	NOUN
ecj-10032	45	50	1	1	NUM
ecj-10032	45	51	)	)	PUNCT
ecj-10032	45	52	.	.	PUNCT
ecj-10032	46	1	abdominal	abdominal	ADJ
ecj-10032	46	2	scans	scan	NOUN
ecj-10032	46	3	further	far	ADV
ecj-10032	46	4	identified	identify	VERB
ecj-10032	46	5	two	two	NUM
ecj-10032	46	6	small	small	ADJ
ecj-10032	46	7	non	non	ADJ
ecj-10032	46	8	occluding	occlude	VERB
ecj-10032	46	9	thrombi	thrombi	NOUN
ecj-10032	46	10	at	at	ADP
ecj-10032	46	11	the	the	DET
ecj-10032	46	12	origin	origin	NOUN
ecj-10032	46	13	of	of	ADP
ecj-10032	46	14	portal	portal	ADJ
ecj-10032	46	15	branches	branch	NOUN
ecj-10032	46	16	to	to	ADP
ecj-10032	46	17	the	the	DET
ecj-10032	46	18	v	v	NOUN
ecj-10032	46	19	and	and	CCONJ
ecj-10032	46	20	vii	vii	PROPN
ecj-10032	46	21	hepatic	hepatic	ADJ
ecj-10032	46	22	segments	segment	NOUN
ecj-10032	46	23	and	and	CCONJ
ecj-10032	46	24	two	two	NUM
ecj-10032	46	25	small	small	ADJ
ecj-10032	46	26	areas	area	NOUN
ecj-10032	46	27	of	of	ADP
ecj-10032	46	28	hypoperfusion	hypoperfusion	NOUN
ecj-10032	46	29	at	at	ADP
ecj-10032	46	30	the	the	DET
ecj-10032	46	31	cortical	cortical	ADJ
ecj-10032	46	32	level	level	NOUN
ecj-10032	46	33	of	of	ADP
ecj-10032	46	34	both	both	DET
ecj-10032	46	35	kidneys	kidney	NOUN
ecj-10032	46	36	,	,	PUNCT
ecj-10032	46	37	suggestive	suggestive	ADJ
ecj-10032	46	38	of	of	ADP
ecj-10032	46	39	ischemic	ischemic	ADJ
ecj-10032	46	40	lesions	lesion	NOUN
ecj-10032	46	41	.	.	PUNCT
ecj-10032	47	1	a	a	DET
ecj-10032	47	2	hematological	hematological	ADJ
ecj-10032	47	3	evaluation	evaluation	NOUN
ecj-10032	47	4	hypothesized	hypothesize	VERB
ecj-10032	47	5	an	an	DET
ecj-10032	47	6	immune	immune	NOUN
ecj-10032	47	7	-	-	PUNCT
ecj-10032	47	8	mediated	mediate	VERB
ecj-10032	47	9	nature	nature	NOUN
ecj-10032	47	10	of	of	ADP
ecj-10032	47	11	the	the	DET
ecj-10032	47	12	thrombosis	thrombosis	NOUN
ecj-10032	47	13	and	and	CCONJ
ecj-10032	47	14	thrombocytopenia	thrombocytopenia	NOUN
ecj-10032	47	15	observed	observe	VERB
ecj-10032	47	16	,	,	PUNCT
ecj-10032	47	17	and	and	CCONJ
ecj-10032	47	18	the	the	DET
ecj-10032	47	19	diagnosis	diagnosis	NOUN
ecj-10032	47	20	of	of	ADP
ecj-10032	47	21	vaccine	vaccine	NOUN
ecj-10032	47	22	-	-	PUNCT
ecj-10032	47	23	induced	induce	VERB
ecj-10032	47	24	thrombotic	thrombotic	ADJ
ecj-10032	47	25	thrombocytopenia	thrombocytopenia	NOUN
ecj-10032	47	26	(	(	PUNCT
ecj-10032	47	27	vitt	vitt	PROPN
ecj-10032	47	28	)	)	PUNCT
ecj-10032	47	29	was	be	AUX
ecj-10032	47	30	assumed	assume	VERB
ecj-10032	47	31	due	due	ADP
ecj-10032	47	32	to	to	ADP
ecj-10032	47	33	the	the	DET
ecj-10032	47	34	recent	recent	ADJ
ecj-10032	47	35	administration	administration	NOUN
ecj-10032	47	36	of	of	ADP
ecj-10032	47	37	chadox1	chadox1	ADJ
ecj-10032	47	38	ncov-19	ncov-19	PROPN
ecj-10032	47	39	vaccine	vaccine	NOUN
ecj-10032	47	40	.	.	PUNCT
ecj-10032	48	1	therefore	therefore	ADV
ecj-10032	48	2	,	,	PUNCT
ecj-10032	48	3	the	the	DET
ecj-10032	48	4	patient	patient	NOUN
ecj-10032	48	5	was	be	AUX
ecj-10032	48	6	admitted	admit	VERB
ecj-10032	48	7	to	to	ADP
ecj-10032	48	8	the	the	DET
ecj-10032	48	9	internal	internal	ADJ
ecj-10032	48	10	medicine	medicine	PROPN
ecj-10032	48	11	department	department	PROPN
ecj-10032	48	12	(	(	PUNCT
ecj-10032	48	13	u.o.c	u.o.c	PROPN
ecj-10032	48	14	.	.	PUNCT
ecj-10032	48	15	medicine	medicine	NOUN
ecj-10032	48	16	2	2	NUM
ecj-10032	48	17	)	)	PUNCT
ecj-10032	48	18	for	for	ADP
ecj-10032	48	19	a	a	DET
ecj-10032	48	20	further	far	ADV
ecj-10032	48	21	diagnostic	diagnostic	ADJ
ecj-10032	48	22	and	and	CCONJ
ecj-10032	48	23	therapeutic	therapeutic	ADJ
ecj-10032	48	24	workup	workup	NOUN
ecj-10032	48	25	.	.	PUNCT
ecj-10032	49	1	treatment	treatment	NOUN
ecj-10032	49	2	included	include	VERB
ecj-10032	49	3	high	high	ADJ
ecj-10032	49	4	dosage	dosage	NOUN
ecj-10032	49	5	steroids	steroid	NOUN
ecj-10032	49	6	with	with	ADP
ecj-10032	49	7	methylprednisolone	methylprednisolone	NOUN
ecj-10032	49	8	(	(	PUNCT
ecj-10032	49	9	1mg	1mg	PROPN
ecj-10032	49	10	/	/	SYM
ecj-10032	49	11	kg	kg	PROPN
ecj-10032	49	12	/	/	SYM
ecj-10032	49	13	die	die	NOUN
ecj-10032	49	14	)	)	PUNCT
ecj-10032	49	15	for	for	ADP
ecj-10032	49	16	one	one	NUM
ecj-10032	49	17	day	day	NOUN
ecj-10032	49	18	followed	follow	VERB
ecj-10032	49	19	by	by	ADP
ecj-10032	49	20	dexamethasone	dexamethasone	NOUN
ecj-10032	49	21	(	(	PUNCT
ecj-10032	49	22	0.6mg	0.6mg	PROPN
ecj-10032	49	23	/	/	SYM
ecj-10032	49	24	kg	kg	NOUN
ecj-10032	49	25	/	/	SYM
ecj-10032	49	26	die	die	NOUN
ecj-10032	49	27	)	)	PUNCT
ecj-10032	49	28	for	for	ADP
ecj-10032	49	29	the	the	DET
ecj-10032	49	30	subsequent	subsequent	ADJ
ecj-10032	49	31	two	two	NUM
ecj-10032	49	32	days	day	NOUN
ecj-10032	49	33	and	and	CCONJ
ecj-10032	49	34	immunoglobulins	immunoglobulin	NOUN
ecj-10032	49	35	(	(	PUNCT
ecj-10032	49	36	500mg	500mg	PROPN
ecj-10032	49	37	/	/	SYM
ecj-10032	49	38	kg	kg	PROPN
ecj-10032	49	39	/	/	SYM
ecj-10032	49	40	die	die	VERB
ecj-10032	49	41	30g	30g	NOUN
ecj-10032	49	42	/	/	SYM
ecj-10032	49	43	die	die	VERB
ecj-10032	49	44	in	in	ADP
ecj-10032	49	45	total	total	NOUN
ecj-10032	49	46	)	)	PUNCT
ecj-10032	49	47	for	for	ADP
ecj-10032	49	48	a	a	DET
ecj-10032	49	49	total	total	NOUN
ecj-10032	49	50	of	of	ADP
ecj-10032	49	51	three	three	NUM
ecj-10032	49	52	days	day	NOUN
ecj-10032	49	53	.	.	PUNCT
ecj-10032	50	1	subcutaneous	subcutaneous	ADJ
ecj-10032	50	2	anticoagulant	anticoagulant	NOUN
ecj-10032	50	3	therapy	therapy	NOUN
ecj-10032	50	4	with	with	ADP
ecj-10032	50	5	fondaparinux	fondaparinux	NOUN
ecj-10032	50	6	was	be	AUX
ecj-10032	50	7	also	also	ADV
ecj-10032	50	8	started	start	VERB
ecj-10032	50	9	at	at	ADP
ecj-10032	50	10	7.5mg	7.5mg	NUM
ecj-10032	50	11	/	/	SYM
ecj-10032	50	12	die	die	NOUN
ecj-10032	50	13	dosage	dosage	NOUN
ecj-10032	50	14	,	,	PUNCT
ecj-10032	50	15	considering	consider	VERB
ecj-10032	50	16	the	the	DET
ecj-10032	50	17	presence	presence	NOUN
ecj-10032	50	18	of	of	ADP
ecj-10032	50	19	arterial	arterial	ADJ
ecj-10032	50	20	thrombosis	thrombosis	NOUN
ecj-10032	50	21	.	.	PUNCT
ecj-10032	51	1	thrombocytopenia	thrombocytopenia	NOUN
ecj-10032	51	2	screening	screen	VERB
ecj-10032	51	3	included	include	VERB
ecj-10032	51	4	viral	viral	ADJ
ecj-10032	51	5	hepatitis	hepatitis	NOUN
ecj-10032	51	6	antigens	antigen	NOUN
ecj-10032	51	7	,	,	PUNCT
ecj-10032	51	8	hiv	hiv	PROPN
ecj-10032	51	9	,	,	PUNCT
ecj-10032	51	10	anti	anti	ADJ
ecj-10032	51	11	-	-	ADJ
ecj-10032	51	12	cardiolipin	cardiolipin	ADJ
ecj-10032	51	13	,	,	PUNCT
ecj-10032	51	14	and	and	CCONJ
ecj-10032	51	15	anti	anti	ADJ
ecj-10032	51	16	-	-	ADJ
ecj-10032	51	17	b2gp1	b2gp1	ADJ
ecj-10032	51	18	antibodies	antibody	NOUN
ecj-10032	51	19	,	,	PUNCT
ecj-10032	51	20	antithrombin	antithrombin	NOUN
ecj-10032	51	21	,	,	PUNCT
ecj-10032	51	22	lupus	lupus	ADJ
ecj-10032	51	23	anti	anti	ADJ
ecj-10032	51	24	-	-	ADJ
ecj-10032	51	25	coagulant	coagulant	ADJ
ecj-10032	51	26	(	(	PUNCT
ecj-10032	51	27	lac	lac	PROPN
ecj-10032	51	28	)	)	PUNCT
ecj-10032	51	29	,	,	PUNCT
ecj-10032	51	30	protein	protein	NOUN
ecj-10032	51	31	c	c	PROPN
ecj-10032	51	32	and	and	CCONJ
ecj-10032	51	33	s	s	PROPN
ecj-10032	51	34	,	,	PUNCT
ecj-10032	51	35	antinuclear	antinuclear	ADJ
ecj-10032	51	36	antibodies	antibodie	VERB
ecj-10032	51	37	(	(	PUNCT
ecj-10032	51	38	ana	ana	PROPN
ecj-10032	51	39	)	)	PUNCT
ecj-10032	51	40	,	,	PUNCT
ecj-10032	51	41	extractable	extractable	ADJ
ecj-10032	51	42	nuclear	nuclear	ADJ
ecj-10032	51	43	antigen	antigen	NOUN
ecj-10032	51	44	antibodies	antibodie	VERB
ecj-10032	51	45	(	(	PUNCT
ecj-10032	51	46	ena	ena	NOUN
ecj-10032	51	47	)	)	PUNCT
ecj-10032	51	48	and	and	CCONJ
ecj-10032	51	49	all	all	PRON
ecj-10032	51	50	tested	test	VERB
ecj-10032	51	51	negative	negative	ADJ
ecj-10032	51	52	.	.	PUNCT
ecj-10032	52	1	screening	screen	VERB
ecj-10032	52	2	for	for	ADP
ecj-10032	52	3	mutation	mutation	NOUN
ecj-10032	52	4	g20210a	g20210a	PROPN
ecj-10032	52	5	and	and	CCONJ
ecj-10032	52	6	v617f	v617f	PROPN
ecj-10032	52	7	of	of	ADP
ecj-10032	52	8	prothrombin	prothrombin	NOUN
ecj-10032	52	9	and	and	CCONJ
ecj-10032	52	10	jak2	jak2	NOUN
ecj-10032	52	11	genes	gene	NOUN
ecj-10032	52	12	,	,	PUNCT
ecj-10032	52	13	respectively	respectively	ADV
ecj-10032	52	14	,	,	PUNCT
ecj-10032	52	15	were	be	AUX
ecj-10032	52	16	also	also	ADV
ecj-10032	52	17	negative	negative	ADJ
ecj-10032	52	18	,	,	PUNCT
ecj-10032	52	19	while	while	SCONJ
ecj-10032	52	20	an	an	DET
ecj-10032	52	21	elisa	elisa	NOUN
ecj-10032	52	22	assay	assay	NOUN
ecj-10032	52	23	highlighted	highlight	VERB
ecj-10032	52	24	the	the	DET
ecj-10032	52	25	presence	presence	NOUN
ecj-10032	52	26	of	of	ADP
ecj-10032	52	27	antibodies	antibody	NOUN
ecj-10032	52	28	against	against	ADP
ecj-10032	52	29	heparin	heparin	ADJ
ecj-10032	52	30	pf4	pf4	NOUN
ecj-10032	52	31	-	-	PUNCT
ecj-10032	52	32	complex	complex	ADJ
ecj-10032	52	33	,	,	PUNCT
ecj-10032	52	34	subsequently	subsequently	ADV
ecj-10032	52	35	verified	verify	VERB
ecj-10032	52	36	with	with	ADP
ecj-10032	52	37	a	a	DET
ecj-10032	52	38	positive	positive	ADJ
ecj-10032	52	39	hipa	hipa	NOUN
ecj-10032	52	40	test	test	NOUN
ecj-10032	52	41	,	,	PUNCT
ecj-10032	52	42	thus	thus	ADV
ecj-10032	52	43	confirming	confirm	VERB
ecj-10032	52	44	the	the	DET
ecj-10032	52	45	diagnosis	diagnosis	NOUN
ecj-10032	52	46	of	of	ADP
ecj-10032	52	47	vitt	vitt	PROPN
ecj-10032	52	48	.	.	PUNCT
ecj-10032	53	1	case	case	NOUN
ecj-10032	53	2	report	report	NOUN
ecj-10032	53	3	figure	figure	NOUN
ecj-10032	53	4	1	1	NUM
ecj-10032	53	5	.	.	PUNCT
ecj-10032	54	1	abdominal	abdominal	ADJ
ecj-10032	54	2	ct	ct	ADJ
ecj-10032	54	3	-	-	PUNCT
ecj-10032	54	4	scan	scan	ADJ
ecj-10032	54	5	frame	frame	NOUN
ecj-10032	54	6	showing	show	VERB
ecj-10032	54	7	a	a	DET
ecj-10032	54	8	non	non	ADJ
ecj-10032	54	9	-	-	ADJ
ecj-10032	54	10	occluding	occluding	ADJ
ecj-10032	54	11	thrombosis	thrombosis	NOUN
ecj-10032	54	12	of	of	ADP
ecj-10032	54	13	the	the	DET
ecj-10032	54	14	superior	superior	ADJ
ecj-10032	54	15	mesenteric	mesenteric	ADJ
ecj-10032	54	16	artery	artery	NOUN
ecj-10032	54	17	.	.	PUNCT
ecj-10032	55	1	figure	figure	NOUN
ecj-10032	55	2	2	2	NUM
ecj-10032	55	3	.	.	PUNCT
ecj-10032	56	1	abdominal	abdominal	ADJ
ecj-10032	56	2	ct	ct	ADJ
ecj-10032	56	3	-	-	PUNCT
ecj-10032	56	4	scan	scan	ADJ
ecj-10032	56	5	frame	frame	NOUN
ecj-10032	56	6	,	,	PUNCT
ecj-10032	56	7	repeated	repeat	VERB
ecj-10032	56	8	on	on	ADP
ecj-10032	56	9	day	day	NOUN
ecj-10032	56	10	4	4	NUM
ecj-10032	56	11	,	,	PUNCT
ecj-10032	56	12	showing	show	VERB
ecj-10032	56	13	resolution	resolution	NOUN
ecj-10032	56	14	of	of	ADP
ecj-10032	56	15	the	the	DET
ecj-10032	56	16	superior	superior	ADJ
ecj-10032	56	17	mesenteric	mesenteric	ADJ
ecj-10032	56	18	artery	artery	NOUN
ecj-10032	56	19	thrombosis	thrombosis	NOUN
ecj-10032	56	20	previously	previously	ADV
ecj-10032	56	21	described	describe	VERB
ecj-10032	56	22	.	.	PUNCT
ecj-10032	57	1	[	[	X
ecj-10032	57	2	emergency	emergency	NOUN
ecj-10032	57	3	care	care	NOUN
ecj-10032	57	4	journal	journal	PROPN
ecj-10032	57	5	2021	2021	NUM
ecj-10032	57	6	;	;	PUNCT
ecj-10032	57	7	17:10032	17:10032	NUM
ecj-10032	57	8	]	]	X
ecj-10032	57	9	[	[	X
ecj-10032	57	10	page	page	NOUN
ecj-10032	57	11	17	17	NUM
ecj-10032	57	12	]	]	X
ecj-10032	57	13	non	non	ADJ
ecj-10032	57	14	-co	-co	PROPN
ecj-10032	57	15	mmerc	mmerc	PROPN
ecj-10032	57	16	ial	ial	PROPN
ecj-10032	57	17	us	us	PROPN
ecj-10032	57	18	e	e	NOUN
ecj-10032	57	19	o	o	X
ecj-10032	57	20	nly	nly	ADV
ecj-10032	57	21	on	on	ADP
ecj-10032	57	22	day	day	NOUN
ecj-10032	57	23	2	2	NUM
ecj-10032	57	24	,	,	PUNCT
ecj-10032	57	25	the	the	DET
ecj-10032	57	26	patient	patient	NOUN
ecj-10032	57	27	complained	complain	VERB
ecj-10032	57	28	of	of	ADP
ecj-10032	57	29	severe	severe	ADJ
ecj-10032	57	30	occipital	occipital	ADJ
ecj-10032	57	31	headache	headache	NOUN
ecj-10032	57	32	,	,	PUNCT
ecj-10032	57	33	and	and	CCONJ
ecj-10032	57	34	a	a	DET
ecj-10032	57	35	head	head	NOUN
ecj-10032	57	36	ct	ct	NOUN
ecj-10032	57	37	scan	scan	PROPN
ecj-10032	57	38	was	be	AUX
ecj-10032	57	39	repeated	repeat	VERB
ecj-10032	57	40	,	,	PUNCT
ecj-10032	57	41	showing	show	VERB
ecj-10032	57	42	no	no	DET
ecj-10032	57	43	acute	acute	ADJ
ecj-10032	57	44	lesions	lesion	NOUN
ecj-10032	57	45	.	.	PUNCT
ecj-10032	58	1	she	she	PRON
ecj-10032	58	2	also	also	ADV
ecj-10032	58	3	presented	present	VERB
ecj-10032	58	4	a	a	DET
ecj-10032	58	5	self	self	NOUN
ecj-10032	58	6	-	-	PUNCT
ecj-10032	58	7	limiting	limit	VERB
ecj-10032	58	8	,	,	PUNCT
ecj-10032	58	9	minor	minor	ADJ
ecj-10032	58	10	episode	episode	NOUN
ecj-10032	58	11	of	of	ADP
ecj-10032	58	12	melena	melena	NOUN
ecj-10032	58	13	on	on	ADP
ecj-10032	58	14	day	day	NOUN
ecj-10032	58	15	3	3	NUM
ecj-10032	58	16	with	with	ADP
ecj-10032	58	17	a	a	DET
ecj-10032	58	18	slight	slight	ADJ
ecj-10032	58	19	decrease	decrease	NOUN
ecj-10032	58	20	in	in	ADP
ecj-10032	58	21	hemoglobin	hemoglobin	NOUN
ecj-10032	58	22	level	level	NOUN
ecj-10032	58	23	.	.	PUNCT
ecj-10032	59	1	at	at	ADP
ecj-10032	59	2	esophagogastroduodenoscopy	esophagogastroduodenoscopy	NOUN
ecj-10032	59	3	,	,	PUNCT
ecj-10032	59	4	erosive	erosive	VERB
ecj-10032	59	5	antral	antral	ADJ
ecj-10032	59	6	gastritis	gastritis	NOUN
ecj-10032	59	7	without	without	ADP
ecj-10032	59	8	signs	sign	NOUN
ecj-10032	59	9	of	of	ADP
ecj-10032	59	10	acute	acute	ADJ
ecj-10032	59	11	bleeding	bleeding	NOUN
ecj-10032	59	12	was	be	AUX
ecj-10032	59	13	described	describe	VERB
ecj-10032	59	14	.	.	PUNCT
ecj-10032	60	1	on	on	ADP
ecj-10032	60	2	day	day	NOUN
ecj-10032	60	3	4	4	NUM
ecj-10032	60	4	,	,	PUNCT
ecj-10032	60	5	a	a	DET
ecj-10032	60	6	ct	ct	NUM
ecj-10032	60	7	abdominal	abdominal	ADJ
ecj-10032	60	8	angiography	angiography	NOUN
ecj-10032	60	9	was	be	AUX
ecj-10032	60	10	performed	perform	VERB
ecj-10032	60	11	,	,	PUNCT
ecj-10032	60	12	showing	show	VERB
ecj-10032	60	13	an	an	DET
ecj-10032	60	14	almost	almost	ADV
ecj-10032	60	15	complete	complete	ADJ
ecj-10032	60	16	resolution	resolution	NOUN
ecj-10032	60	17	of	of	ADP
ecj-10032	60	18	the	the	DET
ecj-10032	60	19	mesenteric	mesenteric	ADJ
ecj-10032	60	20	thrombosis	thrombosis	NOUN
ecj-10032	60	21	previously	previously	ADV
ecj-10032	60	22	described	describe	VERB
ecj-10032	60	23	(	(	PUNCT
ecj-10032	60	24	figure	figure	NOUN
ecj-10032	60	25	2	2	NUM
ecj-10032	60	26	)	)	PUNCT
ecj-10032	60	27	and	and	CCONJ
ecj-10032	60	28	the	the	DET
ecj-10032	60	29	persistence	persistence	NOUN
ecj-10032	60	30	of	of	ADP
ecj-10032	60	31	portal	portal	ADJ
ecj-10032	60	32	branches	branch	NOUN
ecj-10032	60	33	’	'	PUNCT
ecj-10032	60	34	small	small	ADJ
ecj-10032	60	35	thrombotic	thrombotic	ADJ
ecj-10032	60	36	defects	defect	NOUN
ecj-10032	60	37	.	.	PUNCT
ecj-10032	61	1	we	we	PRON
ecj-10032	61	2	observed	observe	VERB
ecj-10032	61	3	a	a	DET
ecj-10032	61	4	progressive	progressive	ADJ
ecj-10032	61	5	increase	increase	NOUN
ecj-10032	61	6	in	in	ADP
ecj-10032	61	7	platelet	platelet	NOUN
ecj-10032	61	8	count	count	NOUN
ecj-10032	61	9	,	,	PUNCT
ecj-10032	61	10	reaching	reach	VERB
ecj-10032	61	11	a	a	DET
ecj-10032	61	12	complete	complete	ADJ
ecj-10032	61	13	restoration	restoration	NOUN
ecj-10032	61	14	on	on	ADP
ecj-10032	61	15	day	day	NOUN
ecj-10032	61	16	6	6	NUM
ecj-10032	61	17	(	(	PUNCT
ecj-10032	61	18	167.000/µl	167.000/µl	NUM
ecj-10032	61	19	)	)	PUNCT
ecj-10032	61	20	.	.	PUNCT
ecj-10032	62	1	due	due	ADP
ecj-10032	62	2	to	to	ADP
ecj-10032	62	3	the	the	DET
ecj-10032	62	4	persistence	persistence	NOUN
ecj-10032	62	5	of	of	ADP
ecj-10032	62	6	hypofibrinogemia	hypofibrinogemia	NOUN
ecj-10032	62	7	,	,	PUNCT
ecj-10032	62	8	we	we	PRON
ecj-10032	62	9	hypothesized	hypothesize	VERB
ecj-10032	62	10	a	a	DET
ecj-10032	62	11	congenital	congenital	ADJ
ecj-10032	62	12	fibrinogen	fibrinogen	NOUN
ecj-10032	62	13	defect	defect	NOUN
ecj-10032	62	14	;	;	PUNCT
ecj-10032	62	15	patient	patient	NOUN
ecj-10032	62	16	’s	’s	PART
ecj-10032	62	17	first	first	ADJ
ecj-10032	62	18	-	-	PUNCT
ecj-10032	62	19	grade	grade	NOUN
ecj-10032	62	20	relatives	relative	NOUN
ecj-10032	62	21	,	,	PUNCT
ecj-10032	62	22	therefore	therefore	ADV
ecj-10032	62	23	,	,	PUNCT
ecj-10032	62	24	underwent	undergo	VERB
ecj-10032	62	25	quantitative	quantitative	ADJ
ecj-10032	62	26	fibrinogen	fibrinogen	NOUN
ecj-10032	62	27	laboratory	laboratory	NOUN
ecj-10032	62	28	dosage	dosage	NOUN
ecj-10032	62	29	showing	show	VERB
ecj-10032	62	30	normal	normal	ADJ
ecj-10032	62	31	results	result	NOUN
ecj-10032	62	32	.	.	PUNCT
ecj-10032	63	1	patient	patient	NOUN
ecj-10032	63	2	’s	’s	PART
ecj-10032	63	3	fibrinogen	fibrinogen	NOUN
ecj-10032	63	4	levels	level	NOUN
ecj-10032	63	5	increased	increase	VERB
ecj-10032	63	6	in	in	ADP
ecj-10032	63	7	the	the	DET
ecj-10032	63	8	subsequent	subsequent	ADJ
ecj-10032	63	9	days	day	NOUN
ecj-10032	63	10	,	,	PUNCT
ecj-10032	63	11	reaching	reach	VERB
ecj-10032	63	12	normal	normal	ADJ
ecj-10032	63	13	values	value	NOUN
ecj-10032	63	14	on	on	ADP
ecj-10032	63	15	day	day	NOUN
ecj-10032	63	16	8	8	NUM
ecj-10032	63	17	.	.	PUNCT
ecj-10032	64	1	following	follow	VERB
ecj-10032	64	2	a	a	DET
ecj-10032	64	3	progressive	progressive	ADJ
ecj-10032	64	4	,	,	PUNCT
ecj-10032	64	5	gradual	gradual	ADJ
ecj-10032	64	6	improvement	improvement	NOUN
ecj-10032	64	7	of	of	ADP
ecj-10032	64	8	clinical	clinical	ADJ
ecj-10032	64	9	conditions	condition	NOUN
ecj-10032	64	10	,	,	PUNCT
ecj-10032	64	11	the	the	DET
ecj-10032	64	12	patient	patient	NOUN
ecj-10032	64	13	was	be	AUX
ecj-10032	64	14	discharged	discharge	VERB
ecj-10032	64	15	on	on	ADP
ecj-10032	64	16	day	day	NOUN
ecj-10032	64	17	13	13	NUM
ecj-10032	64	18	.	.	PUNCT
ecj-10032	65	1	she	she	PRON
ecj-10032	65	2	was	be	AUX
ecj-10032	65	3	in	in	ADP
ecj-10032	65	4	good	good	ADJ
ecj-10032	65	5	clinical	clinical	ADJ
ecj-10032	65	6	condition	condition	NOUN
ecj-10032	65	7	,	,	PUNCT
ecj-10032	65	8	afebrile	afebrile	ADJ
ecj-10032	65	9	,	,	PUNCT
ecj-10032	65	10	eupnoic	eupnoic	ADJ
ecj-10032	65	11	and	and	CCONJ
ecj-10032	65	12	hemodynamically	hemodynamically	ADV
ecj-10032	65	13	stable	stable	ADJ
ecj-10032	65	14	.	.	PUNCT
ecj-10032	66	1	laboratory	laboratory	NOUN
ecj-10032	66	2	testing	testing	NOUN
ecj-10032	66	3	at	at	ADP
ecj-10032	66	4	discharge	discharge	NOUN
ecj-10032	66	5	showed	show	VERB
ecj-10032	66	6	:	:	PUNCT
ecj-10032	66	7	platelets	platelet	VERB
ecj-10032	66	8	224000/µl	224000/µl	NUM
ecj-10032	66	9	,	,	PUNCT
ecj-10032	66	10	hb	hb	PROPN
ecj-10032	66	11	12.2	12.2	NUM
ecj-10032	66	12	mg	mg	PROPN
ecj-10032	66	13	/	/	SYM
ecj-10032	66	14	dl	dl	PROPN
ecj-10032	66	15	,	,	PUNCT
ecj-10032	66	16	fibrinogen	fibrinogen	X
ecj-10032	66	17	510	510	NUM
ecj-10032	66	18	mg	mg	PROPN
ecj-10032	66	19	/	/	SYM
ecj-10032	66	20	dl	dl	PROPN
ecj-10032	66	21	and	and	CCONJ
ecj-10032	66	22	crp	crp	PROPN
ecj-10032	66	23	2	2	NUM
ecj-10032	66	24	mg	mg	PROPN
ecj-10032	66	25	/	/	SYM
ecj-10032	66	26	l.	l.	NOUN
ecj-10032	66	27	treatment	treatment	NOUN
ecj-10032	66	28	with	with	ADP
ecj-10032	66	29	warfarin	warfarin	NOUN
ecj-10032	66	30	for	for	ADP
ecj-10032	66	31	3	3	NUM
ecj-10032	66	32	months	month	NOUN
ecj-10032	66	33	was	be	AUX
ecj-10032	66	34	prescribed	prescribe	VERB
ecj-10032	66	35	at	at	ADP
ecj-10032	66	36	discharge	discharge	NOUN
ecj-10032	66	37	.	.	PUNCT
ecj-10032	67	1	at	at	ADP
ecj-10032	67	2	follow	follow	NOUN
ecj-10032	67	3	-	-	PUNCT
ecj-10032	67	4	up	up	ADP
ecj-10032	67	5	visit	visit	NOUN
ecj-10032	67	6	after	after	ADP
ecj-10032	67	7	one	one	NUM
ecj-10032	67	8	month	month	NOUN
ecj-10032	67	9	,	,	PUNCT
ecj-10032	67	10	the	the	DET
ecj-10032	67	11	patient	patient	NOUN
ecj-10032	67	12	described	describe	VERB
ecj-10032	67	13	a	a	DET
ecj-10032	67	14	further	further	ADJ
ecj-10032	67	15	improvement	improvement	NOUN
ecj-10032	67	16	in	in	ADP
ecj-10032	67	17	general	general	ADJ
ecj-10032	67	18	health	health	NOUN
ecj-10032	67	19	conditions	condition	NOUN
ecj-10032	67	20	.	.	PUNCT
ecj-10032	68	1	good	good	ADJ
ecj-10032	68	2	adherence	adherence	NOUN
ecj-10032	68	3	to	to	ADP
ecj-10032	68	4	therapy	therapy	NOUN
ecj-10032	68	5	with	with	ADP
ecj-10032	68	6	warfarin	warfarin	NOUN
ecj-10032	68	7	was	be	AUX
ecj-10032	68	8	confirmed	confirm	VERB
ecj-10032	68	9	by	by	ADP
ecj-10032	68	10	inr	inr	PROPN
ecj-10032	68	11	dosage	dosage	NOUN
ecj-10032	68	12	.	.	PUNCT
ecj-10032	69	1	discussion	discussion	NOUN
ecj-10032	69	2	this	this	DET
ecj-10032	69	3	case	case	NOUN
ecj-10032	69	4	report	report	NOUN
ecj-10032	69	5	describes	describe	VERB
ecj-10032	69	6	a	a	DET
ecj-10032	69	7	rare	rare	ADJ
ecj-10032	69	8	case	case	NOUN
ecj-10032	69	9	of	of	ADP
ecj-10032	69	10	vaccine	vaccine	NOUN
ecj-10032	69	11	-	-	PUNCT
ecj-10032	69	12	induced	induce	VERB
ecj-10032	69	13	thrombotic	thrombotic	ADJ
ecj-10032	69	14	thrombocytopenia	thrombocytopenia	NOUN
ecj-10032	69	15	with	with	ADP
ecj-10032	69	16	both	both	CCONJ
ecj-10032	69	17	arterial	arterial	NOUN
ecj-10032	69	18	and	and	CCONJ
ecj-10032	69	19	venous	venous	ADJ
ecj-10032	69	20	thrombosis	thrombosis	NOUN
ecj-10032	69	21	following	follow	VERB
ecj-10032	69	22	administration	administration	NOUN
ecj-10032	69	23	of	of	ADP
ecj-10032	69	24	astrazeneca	astrazeneca	PROPN
ecj-10032	69	25	’s	’s	PART
ecj-10032	69	26	chadox1	chadox1	NOUN
ecj-10032	69	27	ncov-19	ncov-19	ADJ
ecj-10032	69	28	vaccine	vaccine	NOUN
ecj-10032	69	29	.	.	PUNCT
ecj-10032	70	1	according	accord	VERB
ecj-10032	70	2	to	to	ADP
ecj-10032	70	3	the	the	DET
ecj-10032	70	4	german	german	ADJ
ecj-10032	70	5	society	society	NOUN
ecj-10032	70	6	of	of	ADP
ecj-10032	70	7	thrombosis	thrombosis	NOUN
ecj-10032	70	8	and	and	CCONJ
ecj-10032	70	9	haemostasis	haemostasis	NOUN
ecj-10032	70	10	(	(	PUNCT
ecj-10032	70	11	gth	gth	PROPN
ecj-10032	70	12	)	)	PUNCT
ecj-10032	70	13	studies	study	NOUN
ecj-10032	70	14	,	,	PUNCT
ecj-10032	70	15	vitt	vitt	X
ecj-10032	70	16	accounts	account	VERB
ecj-10032	70	17	for	for	ADP
ecj-10032	70	18	13	13	NUM
ecj-10032	70	19	cases	case	NOUN
ecj-10032	70	20	out	out	ADP
ecj-10032	70	21	of	of	ADP
ecj-10032	70	22	1.6	1.6	NUM
ecj-10032	70	23	million	million	NUM
ecj-10032	70	24	doses	dose	NOUN
ecj-10032	70	25	of	of	ADP
ecj-10032	70	26	administered	administer	VERB
ecj-10032	70	27	vaccine.10	vaccine.10	NOUN
ecj-10032	70	28	our	our	PRON
ecj-10032	70	29	case	case	NOUN
ecj-10032	70	30	is	be	AUX
ecj-10032	70	31	of	of	ADP
ecj-10032	70	32	particular	particular	ADJ
ecj-10032	70	33	interest	interest	NOUN
ecj-10032	70	34	for	for	ADP
ecj-10032	70	35	simultaneous	simultaneous	ADJ
ecj-10032	70	36	arterial	arterial	NOUN
ecj-10032	70	37	and	and	CCONJ
ecj-10032	70	38	venous	venous	ADJ
ecj-10032	70	39	vascular	vascular	ADJ
ecj-10032	70	40	districts	district	NOUN
ecj-10032	70	41	’	'	PUNCT
ecj-10032	70	42	involvement	involvement	NOUN
ecj-10032	70	43	and	and	CCONJ
ecj-10032	70	44	patient	patient	NOUN
ecj-10032	70	45	’s	’s	PART
ecj-10032	70	46	age	age	NOUN
ecj-10032	70	47	.	.	PUNCT
ecj-10032	71	1	several	several	ADJ
ecj-10032	71	2	reports	report	NOUN
ecj-10032	71	3	of	of	ADP
ecj-10032	71	4	thrombotic	thrombotic	ADJ
ecj-10032	71	5	events	event	NOUN
ecj-10032	71	6	following	follow	VERB
ecj-10032	71	7	the	the	DET
ecj-10032	71	8	administration	administration	NOUN
ecj-10032	71	9	of	of	ADP
ecj-10032	71	10	chadox1	chadox1	ADJ
ecj-10032	71	11	ncov-19	ncov-19	PROPN
ecj-10032	71	12	vaccine	vaccine	NOUN
ecj-10032	71	13	have	have	AUX
ecj-10032	71	14	been	be	AUX
ecj-10032	71	15	described	describe	VERB
ecj-10032	71	16	,	,	PUNCT
ecj-10032	71	17	but	but	CCONJ
ecj-10032	71	18	in	in	ADP
ecj-10032	71	19	most	most	ADJ
ecj-10032	71	20	of	of	ADP
ecj-10032	71	21	them	they	PRON
ecj-10032	71	22	,	,	PUNCT
ecj-10032	71	23	venous	venous	ADJ
ecj-10032	71	24	vessels	vessel	NOUN
ecj-10032	71	25	are	be	AUX
ecj-10032	71	26	mainly	mainly	ADV
ecj-10032	71	27	involved	involve	VERB
ecj-10032	71	28	,	,	PUNCT
ecj-10032	71	29	particularly	particularly	ADV
ecj-10032	71	30	the	the	DET
ecj-10032	71	31	intracranial	intracranial	ADJ
ecj-10032	71	32	venous	venous	ADJ
ecj-10032	71	33	sinuses	sinus	NOUN
ecj-10032	71	34	and	and	CCONJ
ecj-10032	71	35	the	the	DET
ecj-10032	71	36	splanchnic	splanchnic	ADJ
ecj-10032	71	37	venous	venous	ADJ
ecj-10032	71	38	vessels.11,12	vessels.11,12	NOUN
ecj-10032	71	39	our	our	PRON
ecj-10032	71	40	patient	patient	NOUN
ecj-10032	71	41	’s	’s	PART
ecj-10032	71	42	age	age	NOUN
ecj-10032	71	43	also	also	ADV
ecj-10032	71	44	represents	represent	VERB
ecj-10032	71	45	an	an	DET
ecj-10032	71	46	unusual	unusual	ADJ
ecj-10032	71	47	finding	finding	NOUN
ecj-10032	71	48	compared	compare	VERB
ecj-10032	71	49	to	to	ADP
ecj-10032	71	50	previous	previous	ADJ
ecj-10032	71	51	cases	case	NOUN
ecj-10032	71	52	reported	report	VERB
ecj-10032	71	53	in	in	ADP
ecj-10032	71	54	literature	literature	NOUN
ecj-10032	71	55	,	,	PUNCT
ecj-10032	71	56	as	as	SCONJ
ecj-10032	71	57	higher	high	ADJ
ecj-10032	71	58	risk	risk	NOUN
ecj-10032	71	59	subjects	subject	NOUN
ecj-10032	71	60	for	for	ADP
ecj-10032	71	61	vaccine	vaccine	NOUN
ecj-10032	71	62	-	-	PUNCT
ecj-10032	71	63	associated	associate	VERB
ecj-10032	71	64	thrombotic	thrombotic	ADJ
ecj-10032	71	65	events	event	NOUN
ecj-10032	71	66	are	be	AUX
ecj-10032	71	67	usually	usually	ADV
ecj-10032	71	68	women	woman	NOUN
ecj-10032	71	69	younger	young	ADJ
ecj-10032	71	70	than	than	ADP
ecj-10032	71	71	50	50	NUM
ecj-10032	71	72	years	year	NOUN
ecj-10032	71	73	of	of	ADP
ecj-10032	71	74	age	age	NOUN
ecj-10032	71	75	and	and	CCONJ
ecj-10032	71	76	without	without	ADP
ecj-10032	71	77	significant	significant	ADJ
ecj-10032	71	78	past	past	ADJ
ecj-10032	71	79	medical	medical	ADJ
ecj-10032	71	80	history.10	history.10	NOUN
ecj-10032	71	81	due	due	ADP
ecj-10032	71	82	to	to	ADP
ecj-10032	71	83	initial	initial	ADJ
ecj-10032	71	84	gastrointestinal	gastrointestinal	ADJ
ecj-10032	71	85	ischemia	ischemia	NOUN
ecj-10032	71	86	,	,	PUNCT
ecj-10032	71	87	the	the	DET
ecj-10032	71	88	patient	patient	NOUN
ecj-10032	71	89	’s	’s	PART
ecj-10032	71	90	symptoms	symptom	NOUN
ecj-10032	71	91	at	at	ADP
ecj-10032	71	92	presentation	presentation	NOUN
ecj-10032	71	93	are	be	AUX
ecj-10032	71	94	different	different	ADJ
ecj-10032	71	95	from	from	ADP
ecj-10032	71	96	those	those	PRON
ecj-10032	71	97	usually	usually	ADV
ecj-10032	71	98	associated	associate	VERB
ecj-10032	71	99	with	with	ADP
ecj-10032	71	100	venous	venous	ADJ
ecj-10032	71	101	thrombosis	thrombosis	NOUN
ecj-10032	71	102	,	,	PUNCT
ecj-10032	71	103	further	far	ADV
ecj-10032	71	104	challenging	challenge	VERB
ecj-10032	71	105	the	the	DET
ecj-10032	71	106	diagnosis	diagnosis	NOUN
ecj-10032	71	107	.	.	PUNCT
ecj-10032	72	1	in	in	ADP
ecj-10032	72	2	this	this	DET
ecj-10032	72	3	context	context	NOUN
ecj-10032	72	4	,	,	PUNCT
ecj-10032	72	5	recommendations	recommendation	NOUN
ecj-10032	72	6	provided	provide	VERB
ecj-10032	72	7	by	by	ADP
ecj-10032	72	8	different	different	ADJ
ecj-10032	72	9	scientific	scientific	ADJ
ecj-10032	72	10	societies	society	NOUN
ecj-10032	72	11	as	as	ADP
ecj-10032	72	12	the	the	DET
ecj-10032	72	13	international	international	ADJ
ecj-10032	72	14	society	society	NOUN
ecj-10032	72	15	on	on	ADP
ecj-10032	72	16	thrombosis	thrombosis	NOUN
ecj-10032	72	17	and	and	CCONJ
ecj-10032	72	18	haemostasis	haemostasis	NOUN
ecj-10032	72	19	(	(	PUNCT
ecj-10032	72	20	isth	isth	NOUN
ecj-10032	72	21	)	)	PUNCT
ecj-10032	72	22	and	and	CCONJ
ecj-10032	72	23	the	the	DET
ecj-10032	72	24	italian	italian	ADJ
ecj-10032	72	25	society	society	NOUN
ecj-10032	72	26	for	for	ADP
ecj-10032	72	27	the	the	DET
ecj-10032	72	28	study	study	NOUN
ecj-10032	72	29	of	of	ADP
ecj-10032	72	30	haemostasis	haemostasis	NOUN
ecj-10032	72	31	and	and	CCONJ
ecj-10032	72	32	thrombosis	thrombosis	NOUN
ecj-10032	72	33	(	(	PUNCT
ecj-10032	72	34	siset	siset	NOUN
ecj-10032	72	35	)	)	PUNCT
ecj-10032	72	36	,	,	PUNCT
ecj-10032	72	37	as	as	ADV
ecj-10032	72	38	well	well	ADV
ecj-10032	72	39	as	as	ADP
ecj-10032	72	40	case	case	NOUN
ecj-10032	72	41	reports	report	NOUN
ecj-10032	72	42	and	and	CCONJ
ecj-10032	72	43	data	datum	NOUN
ecj-10032	72	44	from	from	ADP
ecj-10032	72	45	the	the	DET
ecj-10032	72	46	literature	literature	NOUN
ecj-10032	72	47	indicated	indicate	VERB
ecj-10032	72	48	the	the	DET
ecj-10032	72	49	need	need	NOUN
ecj-10032	72	50	for	for	ADP
ecj-10032	72	51	laboratory	laboratory	NOUN
ecj-10032	72	52	testing	testing	NOUN
ecj-10032	72	53	characteristics	characteristic	NOUN
ecj-10032	72	54	to	to	PART
ecj-10032	72	55	confirm	confirm	VERB
ecj-10032	72	56	the	the	DET
ecj-10032	72	57	presence	presence	NOUN
ecj-10032	72	58	of	of	ADP
ecj-10032	72	59	vitt	vitt	PROPN
ecj-10032	72	60	,	,	PUNCT
ecj-10032	72	61	i.e.	i.e.	X
ecj-10032	72	62	thrombocytopenia	thrombocytopenia	PROPN
ecj-10032	72	63	,	,	PUNCT
ecj-10032	72	64	hypofibrinogemia	hypofibrinogemia	NOUN
ecj-10032	72	65	and	and	CCONJ
ecj-10032	72	66	increased	increase	VERB
ecj-10032	72	67	d	d	NOUN
ecj-10032	72	68	-	-	PUNCT
ecj-10032	72	69	dimer	dimer	ADJ
ecj-10032	72	70	,	,	PUNCT
ecj-10032	72	71	all	all	PRON
ecj-10032	72	72	suggestive	suggestive	ADJ
ecj-10032	72	73	of	of	ADP
ecj-10032	72	74	a	a	DET
ecj-10032	72	75	consumption	consumption	NOUN
ecj-10032	72	76	coagulopathy.1316	coagulopathy.1316	PROPN
ecj-10032	72	77	conclusions	conclusion	NOUN
ecj-10032	72	78	besides	besides	SCONJ
ecj-10032	72	79	describing	describe	VERB
ecj-10032	72	80	an	an	DET
ecj-10032	72	81	interesting	interesting	ADJ
ecj-10032	72	82	clinical	clinical	ADJ
ecj-10032	72	83	case	case	NOUN
ecj-10032	72	84	of	of	ADP
ecj-10032	72	85	an	an	DET
ecj-10032	72	86	uncommon	uncommon	ADJ
ecj-10032	72	87	variant	variant	NOUN
ecj-10032	72	88	of	of	ADP
ecj-10032	72	89	a	a	DET
ecj-10032	72	90	known	know	VERB
ecj-10032	72	91	infrequent	infrequent	ADJ
ecj-10032	72	92	sars	sar	NOUN
ecj-10032	72	93	-	-	PUNCT
ecj-10032	72	94	cov2	cov2	PROPN
ecj-10032	72	95	vaccine	vaccine	NOUN
ecj-10032	72	96	-	-	PUNCT
ecj-10032	72	97	related	relate	VERB
ecj-10032	72	98	side	side	NOUN
ecj-10032	72	99	effect	effect	NOUN
ecj-10032	72	100	,	,	PUNCT
ecj-10032	72	101	this	this	DET
ecj-10032	72	102	case	case	NOUN
ecj-10032	72	103	report	report	NOUN
ecj-10032	72	104	would	would	AUX
ecj-10032	72	105	like	like	VERB
ecj-10032	72	106	to	to	PART
ecj-10032	72	107	raise	raise	VERB
ecj-10032	72	108	two	two	NUM
ecj-10032	72	109	further	further	ADJ
ecj-10032	72	110	messages	message	NOUN
ecj-10032	72	111	.	.	PUNCT
ecj-10032	73	1	knowledge	knowledge	NOUN
ecj-10032	73	2	of	of	ADP
ecj-10032	73	3	vaccine	vaccine	NOUN
ecj-10032	73	4	’s	’s	PART
ecj-10032	73	5	side	side	NOUN
ecj-10032	73	6	effects	effect	NOUN
ecj-10032	73	7	,	,	PUNCT
ecj-10032	73	8	clinical	clinical	ADJ
ecj-10032	73	9	manifestations	manifestation	NOUN
ecj-10032	73	10	,	,	PUNCT
ecj-10032	73	11	and	and	CCONJ
ecj-10032	73	12	management	management	NOUN
ecj-10032	73	13	may	may	AUX
ecj-10032	73	14	help	help	VERB
ecj-10032	73	15	health	health	NOUN
ecj-10032	73	16	workers	worker	NOUN
ecj-10032	73	17	to	to	PART
ecj-10032	73	18	reassure	reassure	VERB
ecj-10032	73	19	the	the	DET
ecj-10032	73	20	population	population	NOUN
ecj-10032	73	21	about	about	ADP
ecj-10032	73	22	risks	risk	NOUN
ecj-10032	73	23	and	and	CCONJ
ecj-10032	73	24	adverse	adverse	ADJ
ecj-10032	73	25	reactions	reaction	NOUN
ecj-10032	73	26	,	,	PUNCT
ecj-10032	73	27	thus	thus	ADV
ecj-10032	73	28	ensuring	ensure	VERB
ecj-10032	73	29	that	that	SCONJ
ecj-10032	73	30	the	the	DET
ecj-10032	73	31	mass	mass	ADJ
ecj-10032	73	32	campaign	campaign	NOUN
ecj-10032	73	33	vaccination	vaccination	NOUN
ecj-10032	73	34	continues	continue	VERB
ecj-10032	73	35	with	with	ADP
ecj-10032	73	36	even	even	ADV
ecj-10032	73	37	greater	great	ADJ
ecj-10032	73	38	adherence	adherence	NOUN
ecj-10032	73	39	.	.	PUNCT
ecj-10032	74	1	in	in	ADP
ecj-10032	74	2	this	this	DET
ecj-10032	74	3	regard	regard	NOUN
ecj-10032	74	4	,	,	PUNCT
ecj-10032	74	5	it	it	PRON
ecj-10032	74	6	is	be	AUX
ecj-10032	74	7	necessary	necessary	ADJ
ecj-10032	74	8	to	to	PART
ecj-10032	74	9	ensure	ensure	VERB
ecj-10032	74	10	continuous	continuous	ADJ
ecj-10032	74	11	,	,	PUNCT
ecj-10032	74	12	up	up	ADP
ecj-10032	74	13	-	-	PUNCT
ecj-10032	74	14	to	to	ADP
ecj-10032	74	15	-	-	PUNCT
ecj-10032	74	16	date	date	NOUN
ecj-10032	74	17	and	and	CCONJ
ecj-10032	74	18	appropriate	appropriate	ADJ
ecj-10032	74	19	information	information	NOUN
ecj-10032	74	20	to	to	ADP
ecj-10032	74	21	the	the	DET
ecj-10032	74	22	different	different	ADJ
ecj-10032	74	23	population	population	NOUN
ecj-10032	74	24	cohorts	cohort	NOUN
ecj-10032	74	25	to	to	PART
ecj-10032	74	26	increase	increase	VERB
ecj-10032	74	27	the	the	DET
ecj-10032	74	28	awareness	awareness	NOUN
ecj-10032	74	29	of	of	ADP
ecj-10032	74	30	the	the	DET
ecj-10032	74	31	importance	importance	NOUN
ecj-10032	74	32	and	and	CCONJ
ecj-10032	74	33	usefulness	usefulness	NOUN
ecj-10032	74	34	of	of	ADP
ecj-10032	74	35	vaccination	vaccination	NOUN
ecj-10032	74	36	as	as	ADP
ecj-10032	74	37	the	the	DET
ecj-10032	74	38	only	only	ADJ
ecj-10032	74	39	effective	effective	ADJ
ecj-10032	74	40	current	current	ADJ
ecj-10032	74	41	way	way	NOUN
ecj-10032	74	42	of	of	ADP
ecj-10032	74	43	preventing	prevent	VERB
ecj-10032	74	44	the	the	DET
ecj-10032	74	45	spread	spread	NOUN
ecj-10032	74	46	of	of	ADP
ecj-10032	74	47	sars	sar	NOUN
ecj-10032	74	48	-	-	PUNCT
ecj-10032	74	49	cov2	cov2	PROPN
ecj-10032	74	50	infection.8,17	infection.8,17	PROPN
ecj-10032	74	51	on	on	ADP
ecj-10032	74	52	the	the	DET
ecj-10032	74	53	other	other	ADJ
ecj-10032	74	54	hand	hand	NOUN
ecj-10032	74	55	,	,	PUNCT
ecj-10032	74	56	studies	study	NOUN
ecj-10032	74	57	aimed	aim	VERB
ecj-10032	74	58	to	to	PART
ecj-10032	74	59	characterize	characterize	VERB
ecj-10032	74	60	the	the	DET
ecj-10032	74	61	vitt	vitt	PROPN
ecj-10032	74	62	’s	’s	PART
ecj-10032	74	63	clinical	clinical	ADJ
ecj-10032	74	64	and	and	CCONJ
ecj-10032	74	65	molecular	molecular	ADJ
ecj-10032	74	66	mechanisms	mechanism	NOUN
ecj-10032	74	67	are	be	AUX
ecj-10032	74	68	warranted	warrant	VERB
ecj-10032	74	69	.	.	PUNCT
ecj-10032	75	1	several	several	ADJ
ecj-10032	75	2	interesting	interesting	ADJ
ecj-10032	75	3	pathogenic	pathogenic	ADJ
ecj-10032	75	4	and	and	CCONJ
ecj-10032	75	5	therapeutic	therapeutic	ADJ
ecj-10032	75	6	similarities	similarity	NOUN
ecj-10032	75	7	have	have	AUX
ecj-10032	75	8	already	already	ADV
ecj-10032	75	9	been	be	AUX
ecj-10032	75	10	identified	identify	VERB
ecj-10032	75	11	between	between	ADP
ecj-10032	75	12	vitt	vitt	PROPN
ecj-10032	75	13	and	and	CCONJ
ecj-10032	75	14	the	the	DET
ecj-10032	75	15	heparin	heparin	NOUN
ecj-10032	75	16	-	-	PUNCT
ecj-10032	75	17	induced	induce	VERB
ecj-10032	75	18	thrombocytopenia	thrombocytopenia	NOUN
ecj-10032	75	19	(	(	PUNCT
ecj-10032	75	20	hit	hit	PROPN
ecj-10032	75	21	)	)	PUNCT
ecj-10032	75	22	due	due	ADP
ecj-10032	75	23	to	to	ADP
ecj-10032	75	24	the	the	DET
ecj-10032	75	25	presence	presence	NOUN
ecj-10032	75	26	in	in	ADP
ecj-10032	75	27	both	both	DET
ecj-10032	75	28	diseases	disease	NOUN
ecj-10032	75	29	of	of	ADP
ecj-10032	75	30	autoantibodies	autoantibody	NOUN
ecj-10032	75	31	targeting	target	VERB
ecj-10032	75	32	the	the	DET
ecj-10032	75	33	heparin	heparin	NOUN
ecj-10032	75	34	-	-	PUNCT
ecj-10032	75	35	platelet	platelet	NOUN
ecj-10032	75	36	factor	factor	NOUN
ecj-10032	75	37	4	4	NUM
ecj-10032	75	38	(	(	PUNCT
ecj-10032	75	39	pf4	pf4	NOUN
ecj-10032	75	40	)	)	PUNCT
ecj-10032	75	41	complex	complex	NOUN
ecj-10032	75	42	.	.	PUNCT
ecj-10032	76	1	the	the	DET
ecj-10032	76	2	derived	derive	VERB
ecj-10032	76	3	immune	immune	ADJ
ecj-10032	76	4	complexes	complex	NOUN
ecj-10032	76	5	lead	lead	VERB
ecj-10032	76	6	to	to	ADP
ecj-10032	76	7	intense	intense	ADJ
ecj-10032	76	8	intravascular	intravascular	ADJ
ecj-10032	76	9	platelet	platelet	NOUN
ecj-10032	76	10	aggregation	aggregation	NOUN
ecj-10032	76	11	,	,	PUNCT
ecj-10032	76	12	thrombus	thrombus	NOUN
ecj-10032	76	13	formation	formation	NOUN
ecj-10032	76	14	and	and	CCONJ
ecj-10032	76	15	rapid	rapid	ADJ
ecj-10032	76	16	subsequent	subsequent	ADJ
ecj-10032	76	17	platelet	platelet	NOUN
ecj-10032	76	18	count	count	NOUN
ecj-10032	76	19	reduction.6,18	reduction.6,18	PROPN
ecj-10032	76	20	-	-	PUNCT
ecj-10032	76	21	20	20	NUM
ecj-10032	76	22	the	the	DET
ecj-10032	76	23	rapid	rapid	ADJ
ecj-10032	76	24	identification	identification	NOUN
ecj-10032	76	25	of	of	ADP
ecj-10032	76	26	such	such	DET
ecj-10032	76	27	an	an	DET
ecj-10032	76	28	important	important	ADJ
ecj-10032	76	29	analogy	analogy	NOUN
ecj-10032	76	30	between	between	ADP
ecj-10032	76	31	two	two	NUM
ecj-10032	76	32	diseases	disease	NOUN
ecj-10032	76	33	with	with	ADP
ecj-10032	76	34	different	different	ADJ
ecj-10032	76	35	origins	origin	NOUN
ecj-10032	76	36	should	should	AUX
ecj-10032	76	37	encourage	encourage	VERB
ecj-10032	76	38	further	further	ADJ
ecj-10032	76	39	research	research	NOUN
ecj-10032	76	40	in	in	ADP
ecj-10032	76	41	this	this	DET
ecj-10032	76	42	field	field	NOUN
ecj-10032	76	43	with	with	ADP
ecj-10032	76	44	dedicated	dedicated	ADJ
ecj-10032	76	45	attention	attention	NOUN
ecj-10032	76	46	to	to	ADP
ecj-10032	76	47	the	the	DET
ecj-10032	76	48	rarest	rarest	ADJ
ecj-10032	76	49	effects	effect	NOUN
ecj-10032	76	50	of	of	ADP
ecj-10032	76	51	vaccination	vaccination	NOUN
ecj-10032	76	52	therapy	therapy	NOUN
ecj-10032	76	53	.	.	PUNCT
ecj-10032	77	1	references	reference	NOUN
ecj-10032	77	2	1	1	NUM
ecj-10032	77	3	.	.	PUNCT
ecj-10032	77	4	sabeerabi	sabeerabi	PROPN
ecj-10032	77	5	b	b	PROPN
ecj-10032	77	6	,	,	PUNCT
ecj-10032	77	7	vemula	vemula	NOUN
ecj-10032	77	8	s	s	PRON
ecj-10032	77	9	,	,	PUNCT
ecj-10032	77	10	vadde	vadde	ADV
ecj-10032	77	11	r	r	NOUN
ecj-10032	77	12	,	,	PUNCT
ecj-10032	77	13	nagaraju	nagaraju	ADJ
ecj-10032	77	14	gp	gp	NOUN
ecj-10032	77	15	.	.	PUNCT
ecj-10032	78	1	covid-19	covid-19	PROPN
ecj-10032	78	2	:	:	PUNCT
ecj-10032	78	3	where	where	SCONJ
ecj-10032	78	4	is	be	AUX
ecj-10032	78	5	the	the	DET
ecj-10032	78	6	treatment	treatment	NOUN
ecj-10032	78	7	?	?	PUNCT
ecj-10032	79	1	world	world	PROPN
ecj-10032	79	2	j	j	PROPN
ecj-10032	79	3	clin	clin	PROPN
ecj-10032	79	4	oncol	oncol	PROPN
ecj-10032	79	5	2021;12:309	2021;12:309	PROPN
ecj-10032	79	6	-	-	PUNCT
ecj-10032	79	7	22	22	NUM
ecj-10032	79	8	.	.	PUNCT
ecj-10032	80	1	2	2	NUM
ecj-10032	80	2	.	.	NUM
ecj-10032	80	3	orzes	orzes	PROPN
ecj-10032	80	4	n	n	CCONJ
ecj-10032	80	5	,	,	PUNCT
ecj-10032	80	6	pini	pini	X
ecj-10032	80	7	l	l	PROPN
ecj-10032	80	8	,	,	PUNCT
ecj-10032	80	9	levi	levi	PROPN
ecj-10032	80	10	g	g	PROPN
ecj-10032	80	11	,	,	PUNCT
ecj-10032	80	12	et	et	PROPN
ecj-10032	80	13	al	al	PROPN
ecj-10032	80	14	.	.	PUNCT
ecj-10032	81	1	a	a	DET
ecj-10032	81	2	prospective	prospective	ADJ
ecj-10032	81	3	evaluation	evaluation	NOUN
ecj-10032	81	4	of	of	ADP
ecj-10032	81	5	lung	lung	NOUN
ecj-10032	81	6	function	function	NOUN
ecj-10032	81	7	at	at	ADP
ecj-10032	81	8	three	three	NUM
ecj-10032	81	9	and	and	CCONJ
ecj-10032	81	10	six	six	NUM
ecj-10032	81	11	months	month	NOUN
ecj-10032	81	12	in	in	ADP
ecj-10032	81	13	patients	patient	NOUN
ecj-10032	81	14	with	with	ADP
ecj-10032	81	15	previous	previous	ADJ
ecj-10032	81	16	sars	sar	NOUN
ecj-10032	81	17	-	-	PUNCT
ecj-10032	81	18	cov-2	cov-2	NOUN
ecj-10032	81	19	pneumonia	pneumonia	NOUN
ecj-10032	81	20	.	.	PUNCT
ecj-10032	82	1	resp	resp	PROPN
ecj-10032	82	2	med	me	VERB
ecj-10032	82	3	2021;106541	2021;106541	NUM
ecj-10032	82	4	3	3	NUM
ecj-10032	82	5	.	.	PUNCT
ecj-10032	83	1	quek	quek	PROPN
ecj-10032	83	2	e	e	PROPN
ecj-10032	83	3	,	,	PUNCT
ecj-10032	83	4	tahir	tahir	PROPN
ecj-10032	83	5	h	h	PROPN
ecj-10032	83	6	,	,	PUNCT
ecj-10032	83	7	kumar	kumar	PROPN
ecj-10032	83	8	p	p	PROPN
ecj-10032	83	9	,	,	PUNCT
ecj-10032	83	10	et	et	PROPN
ecj-10032	83	11	al	al	PROPN
ecj-10032	83	12	.	.	PROPN
ecj-10032	83	13	treatment	treatment	NOUN
ecj-10032	83	14	of	of	ADP
ecj-10032	83	15	covid-19	covid-19	PROPN
ecj-10032	83	16	:	:	PUNCT
ecj-10032	83	17	a	a	DET
ecj-10032	83	18	review	review	NOUN
ecj-10032	83	19	of	of	ADP
ecj-10032	83	20	current	current	ADJ
ecj-10032	83	21	and	and	CCONJ
ecj-10032	83	22	prospective	prospective	ADJ
ecj-10032	83	23	pharmacotherapies	pharmacotherapie	NOUN
ecj-10032	83	24	.	.	PUNCT
ecj-10032	84	1	br	br	PROPN
ecj-10032	85	1	j	j	PROPN
ecj-10032	85	2	hosp	hosp	PROPN
ecj-10032	85	3	med	med	PROPN
ecj-10032	85	4	(	(	PUNCT
ecj-10032	85	5	lond	lond	PROPN
ecj-10032	85	6	)	)	PUNCT
ecj-10032	85	7	2021;82:1	2021;82:1	NUM
ecj-10032	85	8	-	-	SYM
ecj-10032	85	9	9	9	NUM
ecj-10032	85	10	.	.	NOUN
ecj-10032	85	11	4	4	NUM
ecj-10032	85	12	.	.	X
ecj-10032	86	1	heustess	heustess	ADJ
ecj-10032	86	2	am	am	NOUN
ecj-10032	86	3	,	,	PUNCT
ecj-10032	86	4	allard	allard	PROPN
ecj-10032	86	5	ma	ma	PROPN
ecj-10032	86	6	,	,	PUNCT
ecj-10032	86	7	thompson	thompson	PROPN
ecj-10032	86	8	dk	dk	PROPN
ecj-10032	86	9	,	,	PUNCT
ecj-10032	86	10	fasinu	fasinu	PROPN
ecj-10032	86	11	ps	ps	PROPN
ecj-10032	86	12	.	.	PROPN
ecj-10032	86	13	clinical	clinical	ADJ
ecj-10032	86	14	management	management	NOUN
ecj-10032	86	15	of	of	ADP
ecj-10032	86	16	covid-19	covid-19	PROPN
ecj-10032	86	17	:	:	PUNCT
ecj-10032	86	18	a	a	DET
ecj-10032	86	19	review	review	NOUN
ecj-10032	86	20	of	of	ADP
ecj-10032	86	21	pharmacological	pharmacological	ADJ
ecj-10032	86	22	treatment	treatment	NOUN
ecj-10032	86	23	options	option	NOUN
ecj-10032	86	24	.	.	PUNCT
ecj-10032	87	1	pharmaceuticals	pharmaceutical	NOUN
ecj-10032	87	2	(	(	PUNCT
ecj-10032	87	3	basel	basel	PROPN
ecj-10032	87	4	)	)	PUNCT
ecj-10032	88	1	2021;14:520	2021;14:520	NUM
ecj-10032	88	2	.	.	NOUN
ecj-10032	89	1	5	5	NUM
ecj-10032	89	2	.	.	X
ecj-10032	90	1	sharma	sharma	PROPN
ecj-10032	90	2	o	o	PROPN
ecj-10032	90	3	,	,	PUNCT
ecj-10032	90	4	sultan	sultan	PROPN
ecj-10032	90	5	aa	aa	NOUN
ecj-10032	90	6	,	,	PUNCT
ecj-10032	90	7	ding	ding	NOUN
ecj-10032	90	8	h	h	NOUN
ecj-10032	90	9	,	,	PUNCT
ecj-10032	90	10	triggle	triggle	PROPN
ecj-10032	90	11	cr	cr	PROPN
ecj-10032	90	12	.	.	PUNCT
ecj-10032	91	1	a	a	DET
ecj-10032	91	2	review	review	NOUN
ecj-10032	91	3	of	of	ADP
ecj-10032	91	4	the	the	DET
ecj-10032	91	5	progress	progress	NOUN
ecj-10032	91	6	and	and	CCONJ
ecj-10032	91	7	challenges	challenge	NOUN
ecj-10032	91	8	of	of	ADP
ecj-10032	91	9	developing	develop	VERB
ecj-10032	91	10	a	a	DET
ecj-10032	91	11	vaccine	vaccine	NOUN
ecj-10032	91	12	for	for	ADP
ecj-10032	91	13	covid19	covid19	NOUN
ecj-10032	91	14	.	.	PUNCT
ecj-10032	92	1	front	front	ADJ
ecj-10032	92	2	immunol	immunol	NOUN
ecj-10032	92	3	2020;11:585354	2020;11:585354	PROPN
ecj-10032	92	4	.	.	PROPN
ecj-10032	92	5	6	6	NUM
ecj-10032	92	6	.	.	X
ecj-10032	93	1	rzymski	rzymski	ADJ
ecj-10032	93	2	p	p	NOUN
ecj-10032	93	3	,	,	PUNCT
ecj-10032	93	4	perek	perek	NOUN
ecj-10032	93	5	b	b	NOUN
ecj-10032	93	6	,	,	PUNCT
ecj-10032	93	7	flisiak	flisiak	PROPN
ecj-10032	93	8	r.	r.	PROPN
ecj-10032	93	9	thrombotic	thrombotic	ADJ
ecj-10032	93	10	thrombocytopenia	thrombocytopenia	PROPN
ecj-10032	93	11	after	after	ADP
ecj-10032	93	12	covid-19	covid-19	PROPN
ecj-10032	93	13	vaccination	vaccination	NOUN
ecj-10032	93	14	:	:	PUNCT
ecj-10032	93	15	in	in	ADP
ecj-10032	93	16	search	search	NOUN
ecj-10032	93	17	of	of	ADP
ecj-10032	93	18	the	the	DET
ecj-10032	93	19	underlying	underlying	ADJ
ecj-10032	93	20	mechanism	mechanism	NOUN
ecj-10032	93	21	.	.	PUNCT
ecj-10032	94	1	vaccines	vaccine	NOUN
ecj-10032	94	2	(	(	PUNCT
ecj-10032	94	3	basel	basel	PROPN
ecj-10032	94	4	)	)	PUNCT
ecj-10032	94	5	2021;9:559	2021;9:559	PROPN
ecj-10032	94	6	.	.	PROPN
ecj-10032	94	7	7	7	X
ecj-10032	94	8	.	.	PUNCT
ecj-10032	94	9	doroftei	doroftei	NOUN
ecj-10032	94	10	b	b	PROPN
ecj-10032	94	11	,	,	PUNCT
ecj-10032	94	12	ciobica	ciobica	NOUN
ecj-10032	94	13	a	a	X
ecj-10032	94	14	,	,	PUNCT
ecj-10032	94	15	ilie	ilie	PROPN
ecj-10032	94	16	od	od	PROPN
ecj-10032	94	17	,	,	PUNCT
ecj-10032	94	18	et	et	PROPN
ecj-10032	94	19	al	al	PROPN
ecj-10032	94	20	.	.	PUNCT
ecj-10032	95	1	mini	mini	NOUN
ecj-10032	95	2	-	-	NOUN
ecj-10032	95	3	review	review	NOUN
ecj-10032	95	4	discussing	discuss	VERB
ecj-10032	95	5	the	the	DET
ecj-10032	95	6	reliability	reliability	NOUN
ecj-10032	95	7	and	and	CCONJ
ecj-10032	95	8	efficiency	efficiency	NOUN
ecj-10032	95	9	of	of	ADP
ecj-10032	95	10	covid-19	covid-19	PROPN
ecj-10032	95	11	vaccines	vaccine	NOUN
ecj-10032	95	12	.	.	PUNCT
ecj-10032	96	1	diagnostics	diagnostic	NOUN
ecj-10032	96	2	(	(	PUNCT
ecj-10032	96	3	basel	basel	PROPN
ecj-10032	96	4	)	)	PUNCT
ecj-10032	96	5	2021;11:579	2021;11:579	PROPN
ecj-10032	96	6	.	.	PUNCT
ecj-10032	97	1	8	8	NUM
ecj-10032	97	2	.	.	PUNCT
ecj-10032	98	1	long	long	PROPN
ecj-10032	98	2	b	b	NOUN
ecj-10032	98	3	,	,	PUNCT
ecj-10032	98	4	bridwell	bridwell	PROPN
ecj-10032	98	5	r	r	PROPN
ecj-10032	98	6	,	,	PUNCT
ecj-10032	98	7	gottlieb	gottlieb	PROPN
ecj-10032	98	8	m.	m.	NOUN
ecj-10032	98	9	thrombosis	thrombosis	NOUN
ecj-10032	98	10	with	with	ADP
ecj-10032	98	11	thrombocytopenia	thrombocytopenia	PROPN
ecj-10032	98	12	syndrome	syndrome	NOUN
ecj-10032	98	13	associated	associate	VERB
ecj-10032	98	14	with	with	ADP
ecj-10032	98	15	covid-19	covid-19	PROPN
ecj-10032	98	16	vaccines	vaccine	NOUN
ecj-10032	98	17	.	.	PUNCT
ecj-10032	99	1	am	be	AUX
ecj-10032	99	2	j	j	PROPN
ecj-10032	99	3	emerg	emerg	PROPN
ecj-10032	99	4	med	med	ADJ
ecj-10032	99	5	2021;49:58	2021;49:58	NUM
ecj-10032	99	6	-	-	SYM
ecj-10032	99	7	61	61	NUM
ecj-10032	99	8	.	.	NOUN
ecj-10032	100	1	9	9	NUM
ecj-10032	100	2	.	.	X
ecj-10032	100	3	lavin	lavin	PROPN
ecj-10032	100	4	m	m	PROPN
ecj-10032	100	5	,	,	PUNCT
ecj-10032	100	6	elder	elder	NOUN
ecj-10032	100	7	pt	pt	PROPN
ecj-10032	100	8	,	,	PUNCT
ecj-10032	100	9	o’keeffe	o’keeffe	PROPN
ecj-10032	100	10	d	d	PROPN
ecj-10032	100	11	,	,	PUNCT
ecj-10032	100	12	et	et	PROPN
ecj-10032	100	13	al	al	PROPN
ecj-10032	100	14	.	.	PROPN
ecj-10032	100	15	vaccine	vaccine	NOUN
ecj-10032	100	16	-	-	PUNCT
ecj-10032	100	17	induced	induce	VERB
ecj-10032	100	18	immune	immune	ADJ
ecj-10032	100	19	thrombotic	thrombotic	ADJ
ecj-10032	100	20	thrombocytopenia	thrombocytopenia	NOUN
ecj-10032	100	21	(	(	PUNCT
ecj-10032	100	22	vitt	vitt	PROPN
ecj-10032	100	23	)	)	PUNCT
ecj-10032	100	24	a	a	DET
ecj-10032	100	25	novel	novel	ADJ
ecj-10032	100	26	clinicopathological	clinicopathological	ADJ
ecj-10032	100	27	entity	entity	NOUN
ecj-10032	100	28	with	with	ADP
ecj-10032	100	29	heterogeneous	heterogeneous	ADJ
ecj-10032	100	30	clinical	clinical	ADJ
ecj-10032	100	31	presentations	presentation	NOUN
ecj-10032	100	32	.	.	PUNCT
ecj-10032	101	1	br	br	PROPN
ecj-10032	101	2	j	j	PROPN
ecj-10032	101	3	haematol	haematol	PROPN
ecj-10032	101	4	2021;195:76	2021;195:76	NUM
ecj-10032	101	5	-	-	SYM
ecj-10032	101	6	84	84	NUM
ecj-10032	101	7	.	.	PUNCT
ecj-10032	102	1	10	10	NUM
ecj-10032	102	2	.	.	PUNCT
ecj-10032	103	1	oldenburg	oldenburg	PROPN
ecj-10032	103	2	j	j	PROPN
ecj-10032	103	3	,	,	PUNCT
ecj-10032	103	4	klamroth	klamroth	PROPN
ecj-10032	103	5	r	r	PROPN
ecj-10032	103	6	,	,	PUNCT
ecj-10032	103	7	langer	langer	PROPN
ecj-10032	103	8	f	f	PROPN
ecj-10032	103	9	,	,	PUNCT
ecj-10032	103	10	et	et	PROPN
ecj-10032	103	11	al	al	PROPN
ecj-10032	103	12	.	.	PUNCT
ecj-10032	103	13	diagnosis	diagnosis	NOUN
ecj-10032	103	14	and	and	CCONJ
ecj-10032	103	15	management	management	NOUN
ecj-10032	103	16	of	of	ADP
ecj-10032	103	17	vaccine	vaccine	NOUN
ecj-10032	103	18	-	-	PUNCT
ecj-10032	103	19	related	relate	VERB
ecj-10032	103	20	thrombosis	thrombosis	NOUN
ecj-10032	103	21	following	follow	VERB
ecj-10032	103	22	astrazeneca	astrazeneca	PROPN
ecj-10032	103	23	covid-19	covid-19	PROPN
ecj-10032	103	24	vaccination	vaccination	NOUN
ecj-10032	103	25	:	:	PUNCT
ecj-10032	103	26	guidance	guidance	NOUN
ecj-10032	103	27	statement	statement	NOUN
ecj-10032	103	28	from	from	ADP
ecj-10032	103	29	the	the	DET
ecj-10032	103	30	gth	gth	PROPN
ecj-10032	103	31	.	.	PUNCT
ecj-10032	104	1	hamostaseologie	hamostaseologie	PROPN
ecj-10032	104	2	2021;41:184	2021;41:184	NOUN
ecj-10032	104	3	-	-	SYM
ecj-10032	104	4	9	9	NUM
ecj-10032	104	5	.	.	NOUN
ecj-10032	104	6	11	11	NUM
ecj-10032	104	7	.	.	PUNCT
ecj-10032	105	1	gras	gra	NOUN
ecj-10032	105	2	-	-	PUNCT
ecj-10032	105	3	champel	champel	PROPN
ecj-10032	105	4	v	v	NOUN
ecj-10032	105	5	,	,	PUNCT
ecj-10032	105	6	liabeuf	liabeuf	NOUN
ecj-10032	105	7	s	s	PART
ecj-10032	105	8	,	,	PUNCT
ecj-10032	105	9	baud	baud	VERB
ecj-10032	105	10	m	m	PROPN
ecj-10032	105	11	,	,	PUNCT
ecj-10032	105	12	et	et	PROPN
ecj-10032	105	13	al	al	PROPN
ecj-10032	105	14	.	.	PROPN
ecj-10032	105	15	atypical	atypical	ADJ
ecj-10032	105	16	thrombosis	thrombosis	NOUN
ecj-10032	105	17	associated	associate	VERB
ecj-10032	105	18	with	with	ADP
ecj-10032	105	19	vaxzevria	vaxzevria	NOUN
ecj-10032	105	20	®	®	NOUN
ecj-10032	105	21	(	(	PUNCT
ecj-10032	105	22	astrazeneca	astrazeneca	NOUN
ecj-10032	105	23	)	)	PUNCT
ecj-10032	105	24	vaccine	vaccine	NOUN
ecj-10032	105	25	:	:	PUNCT
ecj-10032	105	26	data	datum	NOUN
ecj-10032	105	27	from	from	ADP
ecj-10032	105	28	the	the	DET
ecj-10032	105	29	french	french	ADJ
ecj-10032	105	30	network	network	NOUN
ecj-10032	105	31	of	of	ADP
ecj-10032	105	32	regional	regional	ADJ
ecj-10032	105	33	pharmacovigilance	pharmacovigilance	NOUN
ecj-10032	105	34	centres	centre	NOUN
ecj-10032	105	35	.	.	PUNCT
ecj-10032	106	1	therapie	therapie	PROPN
ecj-10032	106	2	2021	2021	NUM
ecj-10032	106	3	:	:	PUNCT
ecj-10032	106	4	s0040	s0040	NOUN
ecj-10032	106	5	-	-	ADJ
ecj-10032	106	6	5957(21)00130	5957(21)00130	NUM
ecj-10032	106	7	-	-	PUNCT
ecj-10032	106	8	x.	x.	NOUN
ecj-10032	106	9	case	case	NOUN
ecj-10032	106	10	report	report	NOUN
ecj-10032	106	11	[	[	X
ecj-10032	106	12	page	page	NOUN
ecj-10032	106	13	18	18	NUM
ecj-10032	106	14	]	]	PUNCT
ecj-10032	107	1	[	[	X
ecj-10032	107	2	emergency	emergency	NOUN
ecj-10032	107	3	care	care	NOUN
ecj-10032	107	4	journal	journal	PROPN
ecj-10032	107	5	2021	2021	NUM
ecj-10032	107	6	;	;	PUNCT
ecj-10032	107	7	17:10032	17:10032	NUM
ecj-10032	107	8	]	]	X
ecj-10032	107	9	non	non	ADJ
ecj-10032	107	10	-co	-co	PROPN
ecj-10032	107	11	mmerc	mmerc	PROPN
ecj-10032	107	12	ial	ial	PROPN
ecj-10032	107	13	us	us	PROPN
ecj-10032	107	14	e	e	NOUN
ecj-10032	107	15	o	o	NOUN
ecj-10032	107	16	nly	nly	ADV
ecj-10032	107	17	12	12	NUM
ecj-10032	107	18	.	.	PUNCT
ecj-10032	108	1	pottegård	pottegård	PROPN
ecj-10032	108	2	a	a	PRON
ecj-10032	108	3	,	,	PUNCT
ecj-10032	108	4	lund	lund	PROPN
ecj-10032	108	5	lc	lc	PROPN
ecj-10032	108	6	,	,	PUNCT
ecj-10032	108	7	karlstad	karlstad	PROPN
ecj-10032	108	8	ø	ø	PROPN
ecj-10032	108	9	,	,	PUNCT
ecj-10032	108	10	et	et	PROPN
ecj-10032	108	11	al	al	PROPN
ecj-10032	108	12	.	.	PUNCT
ecj-10032	109	1	arterial	arterial	ADJ
ecj-10032	109	2	events	event	NOUN
ecj-10032	109	3	,	,	PUNCT
ecj-10032	109	4	venous	venous	ADJ
ecj-10032	109	5	thromboembolism	thromboembolism	NOUN
ecj-10032	109	6	,	,	PUNCT
ecj-10032	109	7	thrombocytopenia	thrombocytopenia	PROPN
ecj-10032	109	8	,	,	PUNCT
ecj-10032	109	9	and	and	CCONJ
ecj-10032	109	10	bleeding	bleed	VERB
ecj-10032	109	11	after	after	ADP
ecj-10032	109	12	vaccination	vaccination	NOUN
ecj-10032	109	13	with	with	ADP
ecj-10032	109	14	oxford	oxford	PROPN
ecj-10032	109	15	-	-	PUNCT
ecj-10032	109	16	astrazeneca	astrazeneca	NOUN
ecj-10032	109	17	chadox1	chadox1	PROPN
ecj-10032	109	18	-	-	PUNCT
ecj-10032	109	19	s	s	NOUN
ecj-10032	109	20	in	in	ADP
ecj-10032	109	21	denmark	denmark	NOUN
ecj-10032	109	22	and	and	CCONJ
ecj-10032	109	23	norway	norway	PROPN
ecj-10032	109	24	:	:	PUNCT
ecj-10032	109	25	population	population	NOUN
ecj-10032	109	26	based	base	VERB
ecj-10032	109	27	cohort	cohort	NOUN
ecj-10032	109	28	study	study	NOUN
ecj-10032	109	29	.	.	PUNCT
ecj-10032	110	1	bmj	bmj	PROPN
ecj-10032	110	2	2021;373	2021;373	NUM
ecj-10032	110	3	:	:	PUNCT
ecj-10032	110	4	n1114	n1114	NOUN
ecj-10032	110	5	.	.	NOUN
ecj-10032	110	6	13	13	NUM
ecj-10032	110	7	.	.	X
ecj-10032	111	1	isth	isth	NOUN
ecj-10032	111	2	interim	interim	ADJ
ecj-10032	111	3	guidance	guidance	NOUN
ecj-10032	111	4	for	for	ADP
ecj-10032	111	5	the	the	DET
ecj-10032	111	6	diagnosis	diagnosis	NOUN
ecj-10032	111	7	and	and	CCONJ
ecj-10032	111	8	treatment	treatment	NOUN
ecj-10032	111	9	on	on	ADP
ecj-10032	111	10	vaccineinduced	vaccineinduce	VERB
ecj-10032	111	11	immune	immune	ADJ
ecj-10032	111	12	thrombotic	thrombotic	ADJ
ecj-10032	111	13	thrombocytopenia	thrombocytopenia	PROPN
ecj-10032	111	14	.	.	PUNCT
ecj-10032	112	1	available	available	ADJ
ecj-10032	112	2	from	from	ADP
ecj-10032	112	3	:	:	PUNCT
ecj-10032	112	4	https://www.isth.org/page/covid19	https://www.isth.org/page/covid19	PROPN
ecj-10032	112	5	14	14	PROPN
ecj-10032	112	6	.	.	PUNCT
ecj-10032	113	1	gresele	gresele	PROPN
ecj-10032	113	2	p	p	PROPN
ecj-10032	113	3	,	,	PUNCT
ecj-10032	113	4	marietta	marietta	PROPN
ecj-10032	113	5	m	m	PROPN
ecj-10032	113	6	,	,	PUNCT
ecj-10032	113	7	ageno	ageno	NOUN
ecj-10032	113	8	w	w	PROPN
ecj-10032	113	9	,	,	PUNCT
ecj-10032	113	10	et	et	PROPN
ecj-10032	113	11	al	al	PROPN
ecj-10032	113	12	.	.	PUNCT
ecj-10032	113	13	management	management	NOUN
ecj-10032	113	14	of	of	ADP
ecj-10032	113	15	cerebral	cerebral	ADJ
ecj-10032	113	16	and	and	CCONJ
ecj-10032	113	17	splanchnic	splanchnic	ADJ
ecj-10032	113	18	vein	vein	NOUN
ecj-10032	113	19	thrombosis	thrombosis	NOUN
ecj-10032	113	20	associated	associate	VERB
ecj-10032	113	21	with	with	ADP
ecj-10032	113	22	thrombocytopenia	thrombocytopenia	PROPN
ecj-10032	113	23	in	in	ADP
ecj-10032	113	24	subjects	subject	NOUN
ecj-10032	113	25	previously	previously	ADV
ecj-10032	113	26	vaccinated	vaccinate	VERB
ecj-10032	113	27	with	with	ADP
ecj-10032	113	28	vaxzevria	vaxzevria	NOUN
ecj-10032	113	29	(	(	PUNCT
ecj-10032	113	30	astrazeneca	astrazeneca	NOUN
ecj-10032	113	31	):	):	PUNCT
ecj-10032	113	32	a	a	DET
ecj-10032	113	33	position	position	NOUN
ecj-10032	113	34	statement	statement	NOUN
ecj-10032	113	35	from	from	ADP
ecj-10032	113	36	the	the	DET
ecj-10032	113	37	italian	italian	ADJ
ecj-10032	113	38	society	society	NOUN
ecj-10032	113	39	for	for	ADP
ecj-10032	113	40	the	the	DET
ecj-10032	113	41	study	study	NOUN
ecj-10032	113	42	of	of	ADP
ecj-10032	113	43	haemostasis	haemostasis	NOUN
ecj-10032	113	44	and	and	CCONJ
ecj-10032	113	45	thrombosis	thrombosis	NOUN
ecj-10032	113	46	(	(	PUNCT
ecj-10032	113	47	siset	siset	NOUN
ecj-10032	113	48	)	)	PUNCT
ecj-10032	113	49	.	.	PUNCT
ecj-10032	114	1	blood	blood	NOUN
ecj-10032	114	2	transfus	transfu	NOUN
ecj-10032	114	3	2021;19:281	2021;19:281	PROPN
ecj-10032	114	4	-	-	PUNCT
ecj-10032	114	5	3	3	NUM
ecj-10032	114	6	.	.	NOUN
ecj-10032	114	7	15	15	NUM
ecj-10032	114	8	.	.	PUNCT
ecj-10032	115	1	franchini	franchini	PROPN
ecj-10032	115	2	m	m	PROPN
ecj-10032	115	3	,	,	PUNCT
ecj-10032	115	4	liumbruno	liumbruno	VERB
ecj-10032	115	5	gm	gm	PROPN
ecj-10032	115	6	,	,	PUNCT
ecj-10032	115	7	pezzo	pezzo	PROPN
ecj-10032	115	8	m.	m.	PROPN
ecj-10032	115	9	covid-19	covid-19	PROPN
ecj-10032	115	10	vaccineassociated	vaccineassociate	VERB
ecj-10032	115	11	immune	immune	ADJ
ecj-10032	115	12	thrombosis	thrombosis	NOUN
ecj-10032	115	13	and	and	CCONJ
ecj-10032	115	14	thrombocytopenia	thrombocytopenia	PROPN
ecj-10032	115	15	(	(	PUNCT
ecj-10032	115	16	vitt	vitt	ADV
ecj-10032	115	17	):	):	PUNCT
ecj-10032	115	18	diagnostic	diagnostic	ADJ
ecj-10032	115	19	and	and	CCONJ
ecj-10032	115	20	therapeutic	therapeutic	ADJ
ecj-10032	115	21	recommendations	recommendation	NOUN
ecj-10032	115	22	for	for	ADP
ecj-10032	115	23	a	a	DET
ecj-10032	115	24	new	new	ADJ
ecj-10032	115	25	syndrome	syndrome	NOUN
ecj-10032	115	26	.	.	PUNCT
ecj-10032	116	1	eur	eur	PROPN
ecj-10032	116	2	j	j	PROPN
ecj-10032	116	3	haematol	haematol	NOUN
ecj-10032	116	4	2021;107:173–80	2021;107:173–80	PROPN
ecj-10032	116	5	.	.	PROPN
ecj-10032	116	6	16	16	NUM
ecj-10032	116	7	.	.	PUNCT
ecj-10032	117	1	karnam	karnam	PROPN
ecj-10032	117	2	a	a	DET
ecj-10032	117	3	,	,	PUNCT
ecj-10032	117	4	lacroix	lacroix	NOUN
ecj-10032	117	5	-	-	PUNCT
ecj-10032	117	6	desmazes	desmaze	NOUN
ecj-10032	117	7	s	s	NOUN
ecj-10032	117	8	,	,	PUNCT
ecj-10032	117	9	kaveri	kaveri	PROPN
ecj-10032	117	10	sv	sv	PROPN
ecj-10032	117	11	,	,	PUNCT
ecj-10032	117	12	bayry	bayry	PROPN
ecj-10032	117	13	j.	j.	PROPN
ecj-10032	117	14	vaccineinduced	vaccineinduce	VERB
ecj-10032	117	15	prothrombotic	prothrombotic	ADJ
ecj-10032	117	16	immune	immune	ADJ
ecj-10032	117	17	thrombocytopenia	thrombocytopenia	NOUN
ecj-10032	117	18	(	(	PUNCT
ecj-10032	117	19	vipit	vipit	PROPN
ecj-10032	117	20	):	):	PUNCT
ecj-10032	117	21	consider	consider	VERB
ecj-10032	117	22	ivig	ivig	NOUN
ecj-10032	117	23	batch	batch	NOUN
ecj-10032	117	24	in	in	ADP
ecj-10032	117	25	the	the	DET
ecj-10032	117	26	treatment	treatment	NOUN
ecj-10032	117	27	.	.	PUNCT
ecj-10032	118	1	j	j	PROPN
ecj-10032	118	2	thromb	thromb	PROPN
ecj-10032	118	3	haemost	haemost	VERB
ecj-10032	118	4	2021;19:1838	2021;19:1838	NUM
ecj-10032	118	5	-	-	SYM
ecj-10032	118	6	9	9	NUM
ecj-10032	118	7	.	.	NOUN
ecj-10032	118	8	17	17	NUM
ecj-10032	118	9	.	.	PUNCT
ecj-10032	119	1	hunter	hunter	NOUN
ecj-10032	119	2	pr	pr	PROPN
ecj-10032	119	3	.	.	PUNCT
ecj-10032	119	4	thrombosis	thrombosis	NOUN
ecj-10032	119	5	after	after	ADP
ecj-10032	119	6	covid-19	covid-19	PROPN
ecj-10032	119	7	vaccination	vaccination	NOUN
ecj-10032	119	8	.	.	PUNCT
ecj-10032	120	1	bmj	bmj	PROPN
ecj-10032	120	2	2021;373	2021;373	NUM
ecj-10032	120	3	:	:	PUNCT
ecj-10032	120	4	n958	n958	NUM
ecj-10032	120	5	.	.	NOUN
ecj-10032	121	1	18	18	NUM
ecj-10032	121	2	.	.	X
ecj-10032	122	1	scully	scully	PROPN
ecj-10032	122	2	m	m	PROPN
ecj-10032	122	3	,	,	PUNCT
ecj-10032	122	4	singh	singh	PROPN
ecj-10032	122	5	d	d	PROPN
ecj-10032	122	6	,	,	PUNCT
ecj-10032	122	7	lown	lown	PROPN
ecj-10032	122	8	r	r	NOUN
ecj-10032	122	9	,	,	PUNCT
ecj-10032	122	10	et	et	PROPN
ecj-10032	122	11	al	al	PROPN
ecj-10032	122	12	.	.	PUNCT
ecj-10032	123	1	pathologic	pathologic	PROPN
ecj-10032	123	2	antibodies	antibodie	VERB
ecj-10032	123	3	to	to	PART
ecj-10032	123	4	platelet	platelet	NOUN
ecj-10032	123	5	factor	factor	NOUN
ecj-10032	123	6	4	4	NUM
ecj-10032	123	7	after	after	ADP
ecj-10032	123	8	chadox1	chadox1	NOUN
ecj-10032	123	9	ncov-19	ncov-19	PROPN
ecj-10032	123	10	vaccination	vaccination	NOUN
ecj-10032	123	11	.	.	PUNCT
ecj-10032	124	1	n	n	CCONJ
ecj-10032	124	2	engl	engl	PROPN
ecj-10032	124	3	j	j	PROPN
ecj-10032	124	4	med	me	VERB
ecj-10032	124	5	2021;384:2202	2021;384:2202	PROPN
ecj-10032	124	6	-	-	SYM
ecj-10032	124	7	11	11	NUM
ecj-10032	124	8	.	.	X
ecj-10032	125	1	19	19	NUM
ecj-10032	125	2	.	.	PUNCT
ecj-10032	126	1	douxfils	douxfils	PROPN
ecj-10032	126	2	j	j	PROPN
ecj-10032	126	3	,	,	PUNCT
ecj-10032	126	4	favresse	favresse	PROPN
ecj-10032	126	5	j	j	PROPN
ecj-10032	126	6	,	,	PUNCT
ecj-10032	126	7	dogné	dogné	PROPN
ecj-10032	126	8	jm	jm	PROPN
ecj-10032	126	9	,	,	PUNCT
ecj-10032	126	10	et	et	PROPN
ecj-10032	126	11	al	al	PROPN
ecj-10032	126	12	.	.	PUNCT
ecj-10032	127	1	hypotheses	hypothesis	NOUN
ecj-10032	127	2	behind	behind	ADP
ecj-10032	127	3	the	the	DET
ecj-10032	127	4	very	very	ADV
ecj-10032	127	5	rare	rare	ADJ
ecj-10032	127	6	cases	case	NOUN
ecj-10032	127	7	of	of	ADP
ecj-10032	127	8	thrombosis	thrombosis	NOUN
ecj-10032	127	9	with	with	ADP
ecj-10032	127	10	thrombocytopenia	thrombocytopenia	PROPN
ecj-10032	127	11	syndrome	syndrome	NOUN
ecj-10032	127	12	after	after	ADP
ecj-10032	127	13	sars	sar	NOUN
ecj-10032	127	14	-	-	PUNCT
ecj-10032	127	15	cov-2	cov-2	PART
ecj-10032	127	16	vaccination	vaccination	NOUN
ecj-10032	127	17	.	.	PUNCT
ecj-10032	128	1	thromb	thromb	NOUN
ecj-10032	128	2	res	re	NOUN
ecj-10032	128	3	2021;203:163	2021;203:163	NUM
ecj-10032	128	4	-	-	SYM
ecj-10032	128	5	71	71	NUM
ecj-10032	128	6	.	.	NOUN
ecj-10032	128	7	20	20	NUM
ecj-10032	128	8	.	.	PUNCT
ecj-10032	128	9	patriquin	patriquin	PROPN
ecj-10032	128	10	cj	cj	PROPN
ecj-10032	128	11	,	,	PUNCT
ecj-10032	128	12	laroche	laroche	PROPN
ecj-10032	128	13	v	v	PROPN
ecj-10032	128	14	,	,	PUNCT
ecj-10032	128	15	selby	selby	PROPN
ecj-10032	128	16	r	r	PROPN
ecj-10032	128	17	,	,	PUNCT
ecj-10032	128	18	et	et	PROPN
ecj-10032	128	19	al	al	PROPN
ecj-10032	128	20	.	.	PUNCT
ecj-10032	129	1	therapeutic	therapeutic	ADJ
ecj-10032	129	2	plasma	plasma	NOUN
ecj-10032	129	3	exchange	exchange	NOUN
ecj-10032	129	4	in	in	ADP
ecj-10032	129	5	vaccine	vaccine	NOUN
ecj-10032	129	6	-	-	PUNCT
ecj-10032	129	7	induced	induce	VERB
ecj-10032	129	8	immune	immune	ADJ
ecj-10032	129	9	thrombotic	thrombotic	ADJ
ecj-10032	129	10	thrombocytopenia	thrombocytopenia	PROPN
ecj-10032	129	11	.	.	PUNCT
ecj-10032	130	1	n	n	PROPN
ecj-10032	130	2	engl	engl	PROPN
ecj-10032	130	3	j	j	PROPN
ecj-10032	130	4	med	med	PROPN
ecj-10032	130	5	26;385:857	26;385:857	NUM
ecj-10032	130	6	-	-	SYM
ecj-10032	130	7	9	9	NUM
ecj-10032	130	8	.	.	PUNCT
ecj-10032	130	9	case	case	NOUN
ecj-10032	130	10	report	report	NOUN
ecj-10032	130	11	[	[	X
ecj-10032	130	12	emergency	emergency	NOUN
ecj-10032	130	13	care	care	NOUN
ecj-10032	130	14	journal	journal	PROPN
ecj-10032	130	15	2021	2021	NUM
ecj-10032	130	16	;	;	PUNCT
ecj-10032	130	17	17:10032	17:10032	NUM
ecj-10032	130	18	]	]	X
ecj-10032	131	1	[	[	X
ecj-10032	131	2	page	page	NOUN
ecj-10032	131	3	19	19	NUM
ecj-10032	131	4	]	]	X
ecj-10032	131	5	non	non	ADJ
ecj-10032	131	6	-co	-co	PROPN
ecj-10032	131	7	mmerc	mmerc	PROPN
ecj-10032	131	8	ial	ial	PROPN
ecj-10032	131	9	us	us	PROPN
ecj-10032	131	10	e	e	NOUN
ecj-10032	131	11	o	o	NOUN
ecj-10032	131	12	nly	nly	ADV